Fintel News

Jefferies Upgrades Chagee Holdings Limited - Depositary Receipt to Buy from Hold

2026-10-22T00:02:01Z

Fintel reports that on October 21, 2026, Jefferies upgraded their outlook for Chagee Holdings Limited - Depositary Receipt (NASDAQGS:CHA) (DUSE:I0K) from Hold to Buy.

On the day of the rating action, October 21, 2026, the stock closed at $12.94, following a pre-action close of $12.48 on October 20, 2026. This latest close represents a price change of +5.29% over one week, compared to the baseline close of $12.29 on October 14, 2026. Over a one-month period, the stock experienced a price change of +5.89% from its baseline close of $12.22 on September 21, 2026.

Separately from the individual rating by Jefferies, the current consensus target mean for the stock was $14.88 with a median of $15.50 as of October 2, 2026, representing an implied change of +15.00%. This current consensus target mean was unchanged from the prior consensus target mean of $14.88 recorded on September 15, 2026, showing a consensus target revision of 0.00%.

As of the current recommendation period on October 1, 2026, the aggregate analyst recommendations consisted of 2 strong buy, 8 buy, 4 hold, 0 sell, and 0 strong sell ratings, totaling 14 recommendations. This distribution reflects 71.4% positive, 28.6% hold, and 0.0% negative recommendations. These figures are identical to the prior recommendation period on September 1, 2026, which also recorded 2 strong buy, 8 buy, 4 hold, 0 sell, and 0 strong sell ratings, totaling 14 recommendations with 71.4% positive, 28.6% hold, and 0.0% negative recommendations.

In its latest earnings report on August 28, 2026, Chagee Holdings Limited - Depositary Receipt reported an actual EPS of 2.54, which exceeded the estimated EPS of 2.3823, representing a surprise of +6.62%. The company's actual revenue for the period was $3,414,604,000.00, compared to the estimated revenue of $3,610,963,786.00.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 21, 2026	Jefferies	Hold	Buy	upgrade

Evercore ISI Group Downgrades Ally Financial to In-Line from Outperform

2026-10-21T23:39:21Z

Fintel reports that on October 21, 2026, Evercore ISI Group downgraded their outlook for Ally Financial (NYSE:ALLY) (LSE:0HD0) from Outperform to In-Line. This rating action follows a prior action by Evercore ISI Group on April 21, 2026, when the firm maintained its Outperform rating on the stock.

Ally Financial Inc., based in the United States, operates primarily in the financial services sector. Originally established as GMAC Inc. (General Motors Acceptance Corporation), the company rebranded to Ally Financial in 2010 and provides auto financing, personal and commercial banking, mortgage loans, and corporate financing. On October 21, 2026, the company's stock closed at $38.70, following a pre-action close of $37.97 on October 20, 2026. This latest close represents a one-week price change of +5.33% from the baseline close of $36.74 on October 14, 2026, and a one-month price change of -2.98% from the baseline close of $39.89 on September 21, 2026.

The rating action occurred one day after Ally Financial reported its latest earnings on October 20, 2026. The company reported actual earnings per share (EPS) of 1.34, compared to the estimated EPS of 1.3667, which represents an EPS surprise of -1.95%. Ally Financial also reported actual revenue of $2,332,000,000.00, compared to the estimated revenue of $2,345,117,914.00.

Separately from Evercore ISI Group's individual rating, the broader analyst consensus target for Ally Financial was recorded at a mean of $53.10 and a median of $55.59 as of October 2, 2026. This mean target implies a change of +37.22% from the stock's valuation at that time, down from a prior consensus target mean of $55.69 on September 15, 2026, which represents a revision of -4.65%. For the recommendation period of September 1, 2026, the aggregate recommendation pool consisted of 24 total recommendations, including 5 strong buy, 14 buy, 5 hold, 0 sell, and 0 strong sell ratings. This distribution reflects 79.2% positive recommendations and 20.8% hold recommendations, which remained unchanged from the prior recommendation period of August 1, 2026.

On the same day as the downgrade, October 21, 2026, JP Morgan maintained its Overweight rating on Ally Financial. This was part of a broader series of recent analyst actions. Previously, on October 12, 2026, JP Morgan maintained its Overweight rating, while Morgan Stanley downgraded the stock from Overweight to Equal-Weight. Other recent actions include RBC Capital maintaining an Outperform rating on October 9, 2026, and both Raymond James and TD Cowen maintaining Strong Buy and Buy ratings, respectively, on October 6, 2026.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 21, 2026	Evercore ISI Group	Outperform	In-Line	downgrade
October 21, 2026	JP Morgan	Overweight	Overweight	maintained
October 12, 2026	JP Morgan	Overweight	Overweight	maintained
October 12, 2026	Morgan Stanley	Overweight	Equal-Weight	downgrade
October 9, 2026	RBC Capital	Outperform	Outperform	maintained
October 6, 2026	Raymond James	Strong Buy	Strong Buy	maintained
October 6, 2026	TD Cowen	Buy	Buy	maintained

UBS Upgrades Clean Harbors to Buy from Neutral

2026-10-21T21:48:19Z

Fintel reports that on October 21, 2026, UBS upgraded their outlook for Clean Harbors (NYSE:CLH) (BMV:CLH1) from Neutral to Buy.

This upgrade follows a prior action by UBS on May 14, 2026, when the firm maintained its Neutral rating on the stock. Other financial institutions have also recently updated their views on Clean Harbors. On October 15, 2026, Citigroup maintained its Buy rating. Prior to that, TD Cowen maintained its Buy rating on October 14, 2026, and Barclays maintained its Equal-Weight rating on October 8, 2026.

The broader analyst consensus for Clean Harbors as of October 1, 2026, shows a total of 22 recommendations, consisting of 8 strong buy, 8 buy, 6 hold, 0 sell, and 0 strong sell ratings. This represents 72.7% positive, 27.3% hold, and 0.0% negative recommendations. In the prior period as of September 1, 2026, there were 21 total recommendations, including 7 strong buy, 8 buy, 6 hold, 0 sell, and 0 strong sell ratings, which represented 71.4% positive, 28.6% hold, and 0.0% negative recommendations. The current consensus target price as of October 2, 2026, features a mean target of $362.03 and a median target of $365.16, representing an implied change of +14.47%. This is a decrease from the prior consensus target mean of $365.98 recorded on September 15, 2026, representing a consensus target revision of -1.08%.

Clean Harbors closed at $316.28 on October 20, 2026, which was the pre-action close. This latest close represents a one-week price change of -0.35% from a baseline close of $317.38 on October 13, 2026, and a one-month price change of +0.15% from a baseline close of $315.80 on September 18, 2026. Clean Harbors, Inc. operates within the environmental, energy, and industrial services sectors, providing hazardous waste disposal, environmental cleanup, emergency response, and industrial cleaning services.

In its latest earnings report on July 29, 2026, Clean Harbors reported an actual EPS of 3.22, which beat the estimate of 2.8302 by a surprise of +13.77%. The company reported actual revenue of $1,735,005,000.00, compared to the estimated revenue of $1,657,604,425.00. The company's upcoming earnings announcement is scheduled for October 28, 2026, during the bmo session.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 21, 2026	UBS	Neutral	Buy	upgrade
October 15, 2026	Citigroup	Buy	Buy	maintained
October 14, 2026	TD Cowen	Buy	Buy	maintained
October 8, 2026	Barclays	Equal-Weight	Equal-Weight	maintained

B. Riley Securities initiates coverage of QumulusAI with Buy

2026-10-21T21:12:14Z

Fintel reports that on October 21, 2026, B. Riley Securities initiated coverage of QumulusAI (NASDAQGM:QMLS) with a Buy recommendation.

Prior to this coverage initiation, the stock closed at $3.56 on October 20, 2026. QumulusAI recorded a one-week price change of -12.75% from its baseline close of $4.08 on October 13, 2026. Over a one-month period, the stock recorded a price change of -51.23% from its baseline close of $7.30 on September 18, 2026.

Separately from the individual rating issued by B. Riley Securities, the broader consensus target mean for QumulusAI stood at $23.46 as of October 2, 2026. This mean target is identical to the consensus median target of $23.46 recorded on the same date. This consensus target represents an implied change of +558.99% relative to the stock's closing price of $3.56 on October 20, 2026.

The aggregate analyst sentiment during the current recommendation period, which commenced on September 1, 2026, shows a total of 7 recommendations. The breakdown of these recommendations includes 2 strong buy, 4 buy, and 1 hold ratings. Based on this distribution, positive recommendations account for 85.7% of the total, while hold recommendations represent 14.3%.

Other analyst firms have also recently published coverage on QumulusAI. On October 16, 2026, Compass Point initiated coverage on the company, assigning a Buy recommendation. Additionally, on September 30, 2026, Chardan Capital maintained its Buy recommendation on the stock, with both the from rating and to rating recorded as Buy.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 21, 2026	B. Riley Securities		Buy	initiated coverage
October 16, 2026	Compass Point		Buy	initiated coverage
September 30, 2026	Chardan Capital	Buy	Buy	maintained

News Corporation Reports Progress on $1 billion Repurchase Program

2026-10-21T20:49:55Z

News Corporation reported updates on its stock repurchase program, under which the company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. As of the previous day on which securities were bought back, which was 20/10/2026, the company has purchased approximately US$542,866,726 worth of Class A and Class B shares under the program, which was authorized as of July 15, 2025. The buy-back program is intended to enhance shareholder value.

According to daily buy-back notifications, News Corporation repurchased 54,641 shares of Class A common stock on the previous day of 20/10/2026, for a total consideration of US$1,669,550.29. Prior to that, the total number of Class A securities bought back was 13,446,956 for a total consideration of US$354,954,752.85.

For Class B common stock, the company repurchased 23,784 shares on 20/10/2026, for a total consideration of US$793,893.27. Before that day, the total number of Class B securities bought back was 6,222,939 for a total consideration of US$185,448,529.67. Goldman Sachs & Co. LLC is acting as the broker for the program.

View the company filing on SEC.gov

Clean Energy Technologies, Inc. Enters into $500,000 Securities Purchase Agreement with Falcon Venture Limited

2026-10-21T20:49:48Z

On October 18, 2026, Clean Energy Technologies, Inc. entered into a securities purchase agreement with Falcon Venture Limited, a Samoa incorporated company, pursuant to which the Company sold, and Falcon purchased, a convertible promissory note in the principal amount of $500,000 for a purchase price of $500,000. The purchase price had already been received by the Company, and on October 18, 2026, the Company issued the note to Falcon. The agreement requires that the proceeds from the transaction be used for business development and the payment of Company obligations.

The note matures on October 18, 2027, accrues interest at 8% per annum, and is convertible 6 months after issuance into shares of the Company’s common stock at the election of the holder at a conversion price equal to 85% of the lowest traded price during the ten trading days prior to the conversion date. However, the holder may not convert the note to the extent that such conversion would result in the holder’s beneficial ownership of the Company’s common stock being in excess of 9.99% of the Company’s issued and outstanding common stock, or when the shareholder approval required by Nasdaq Rule 5635(d) has not been obtained and conversion would result in more than 2,432,004 shares of Company common stock being issued in the aggregate. Additionally, the holder of the note is entitled to deduct $1,750 from the conversion amount in each note conversion to cover the holder’s fees associated with the conversion.

View the company filing on SEC.gov

Azul S.A. Announces Capital Increase of BRL 512,811,716.28 Following American Airlines Warrant Exercise

2026-10-21T20:49:42Z

Azul S.A. announced that on October 19th, 2026, it received a notice of exercise from American Airlines, Inc. for all of its warrants to subscribe for common shares. The exercise comprised 3,958,429,263,261 Series 1 (AZUL11) American Subscription Warrants and 5,449,247 Series 4 (AZUL19) American Subscription Warrants. American informed the company that it would proceed to deposit the resulting common shares into the company's ADR program.

On October 20, 2026, the Board of Directors confirmed a total share capital increase of BRL 512,811,716.28 resulting from the exercise of the warrants. This included the exercise of the American warrants and additional warrants by other investors, consisting of 43,990,650,000 Series 1, 699,750,000 Series 2, 12,978,600,000 Series 3, and 48,091 Series 4 subscription warrants. A total of 31,838,775 common shares were issued to American, and 432,551 common shares were issued to other investors, leaving Azul S.A. with 400,829,250 common shares outstanding.

Consequent to the consummation of American's investment, Mr. John Peter Rodgerson resigned from his positions as a member of the Board of Directors and the Strategy Committee, though he remains the Chief Executive Officer. His alternate, Mr. Jeff Ogar, assumed the vacant positions on the Board of Directors and the Strategy Committee.

View the company filing on SEC.gov

OPAL Fuels Inc. Announces Planned Retirement of Co-CEO Jonathan Maurer

2026-10-21T20:49:37Z

OPAL Fuels Inc. announced that on October 19, 2026, Jonathan Maurer, Co-Chief Executive Officer of the company, notified the company that he intends to retire from his role as Co-Chief Executive Officer effective as of March 31, 2027. Mr. Maurer plans to be available to the company in a Senior Advisor role for an appropriate period of time following his retirement to support a smooth transition. Effective upon Mr. Maurer's retirement, Adam Comora will become the company's sole Chief Executive Officer.

Except for the existing terms of Mr. Maurer’s outstanding equity awards, there are currently no compensation agreements or arrangements in place regarding Mr. Maurer’s retirement or subsequent Senior Advisor Role. Mr. Maurer is not a party to an employment agreement with the company.

According to the company's press release, Mr. Maurer has been Co-Chief Executive Officer of OPAL Fuels since April 2021, after the company was formed. Prior to that Mr. Maurer was employed by FORTISTAR, the company's majority shareholder, since October 1998.

The company additionally announced that the Board has commenced an executive search for a President, who will report to Adam Comora.

View the company filing on SEC.gov

BHP Group Limited Reports Q1 FY27 Operational Review and Olympic Dam Resource Update

2026-10-21T20:49:29Z

BHP Group Limited reported its operational review for the quarter ended 30 September 2026, maintaining its full year production guidance. Total copper production decreased 19% to 401 kt, reflecting planned grade declines and scheduled maintenance, alongside temporary disruptions from severe weather in Chile, stops for safety, and a conveyor failure at Carrapateena. The average realised price for copper was US$7.01/lb, representing an increase of 53% compared to Q1 FY26. Escondida copper production decreased 23% to 252.6 kt on a 100% basis, impacted by a fatal incident on 23 September that led to a temporary suspension of mining activities, as well as planned lower feed grades of 0.81%.

In bulk commodities, iron ore production increased 4% to 66.5 Mt, with Western Australia Iron Ore achieving record Q1 production at both the mine and port despite significant planned maintenance. Steelmaking coal production at BHP Mitsubishi Alliance increased 1% to 4.9 Mt, although operations were temporarily suspended following a fatal incident at Peak Downs. Energy coal production at New South Wales Energy Coal rose 26% to 4.4 Mt, driven by higher bypass coal and improved wash plant throughput.

For its growth projects, BHP Group Limited approved US$0.8 bn of pre-commitment funding on a 100% basis for the Escondida New Concentrator in Chile. The Jansen Stage 1 potash project in Canada is 87% complete and remains on track for first production in mid-2027. Additionally, the company announced the first-time reporting of an underground block cave Mineral Resource at Olympic Dam in South Australia, estimated at 10,730 Mt at 0.59 % Cu, 0.19 kg/t U3O8, 0.21 g/t Au, and 1 g/t Ag.

View the company filing on SEC.gov

Danaher Reports Third Quarter 2026 Results

2026-10-21T20:49:22Z

Danaher Corporation announced its financial results for the third quarter ended September 25, 2026. The company reported net earnings of $1.2 billion, or $1.71 per diluted common share, representing an increase of 34.5% year-over-year. Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11. Revenues for the quarter increased 8.5% year-over-year to $6.6 billion, while non-GAAP core revenue increased 3.0% year-over-year.

Operating cash flow for the quarter was $1.9 billion and non-GAAP free cash flow was $1.6 billion. Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year. For the fourth quarter 2026, the company anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0% range year-over-year, with respiratory revenue expected to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%.

For the full year 2026, Danaher Corporation is increasing its adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62, compared to its previous guidance of $8.45 to $8.60. The company's full year guidance assumes an estimated amortization of acquisition-related intangible assets of $1.9 billion for the year ending December 31, 2026, and an estimated impact of foreign currency on sales that is expected to increase sales by 1.0% in the full year.

View the company filing on SEC.gov

Mannatech, Incorporated Dismisses BDO USA, P.C. and Appoints CBIZ CPAs P.C. on October 15, 2026

2026-10-21T20:49:16Z

On October 15, 2026, the Audit Committee of the Board of Directors of Mannatech, Incorporated approved the dismissal of BDO USA, P.C. as the Company's independent registered public accounting firm, effective October 15, 2026.

BDO's reports on the Company's consolidated financial statements as of and for the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that BDO's report for the fiscal year ended December 31, 2025 contained an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.

On October 15, 2026, the Audit Committee approved the engagement of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, beginning with the review of the Company's condensed consolidated financial statements for the quarter ended September 30, 2026.

During the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through October 15, 2026, there were no disagreements with BDO on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.

View the company filing on SEC.gov

reAlpha Tech Corp. Board Approves Updated Non-Executive Director Compensation Policy

2026-10-21T20:49:09Z

On October 21, 2026, reAlpha Tech Corp. reported that its Board of Directors, upon recommendation of the Compensation Committee of the Board, approved an updated non-executive director compensation policy. This updated policy is effective as of March 9, 2026. Under the terms of the updated policy, the non-executive directors of the Board will be eligible to receive a total annual compensation of $100,000 for their service.

The total annual compensation is structured to consist of $75,000 in shares of the Company’s common stock, par value $0.001 per share, and cash compensation in an amount equal to $25,000. The stock portion will be issued in quarterly installments on January 30, April 30, July 30 and October 30 of each fiscal year, or $18,750 per quarter. The number of shares issued in each quarterly installment is determined by dividing $18,750 by the 10-day volume weighted average price of the Common Stock, as reported on Nasdaq, ending on and including the grant date. The cash compensation is payable in quarterly installments of $6,250 on the same dates as the Share Awards.

View the company filing on SEC.gov

Thermo Fisher Scientific Inc. Reports Third Quarter 2026 Results

2026-10-21T20:49:02Z

Thermo Fisher Scientific Inc. reported its financial results for the third quarter ended September 26, 2026. Revenue for the quarter grew 9% to $12.14 billion, compared with $11.12 billion in the third quarter of 2025, with organic revenue growth of 6%. GAAP diluted earnings per share for the quarter grew 9% to $4.64, while adjusted earnings per share grew 15% to $6.68.

GAAP operating income for the third quarter of 2026 was $2.26 billion, which is 17% higher than the year-ago quarter, with a GAAP operating margin of 18.6% compared with 17.4% in the third quarter of 2025. Adjusted operating income for the quarter was $2.97 billion, representing a 15% increase compared to the prior year's quarter, with an adjusted operating margin of 24.5% compared with 23.3% in the third quarter of 2025.

During the quarter, Thermo Fisher Scientific Inc. completed its previously announced divestiture of its microbiology business. The company also partnered with Mayo Clinic to launch Precure, an initiative combining data from more than one million patient samples with its proteomics ecosystem, opened its first AI-Automation Innovation Center in South Korea, and opened a highly automated distribution center in Kentucky.

View the company filing on SEC.gov

KB Financial Group Inc. Reports Largest Shareholder Stake Decreased to 9.18%

2026-10-21T20:48:54Z

KB Financial Group Inc. reported on October 21, 2026, that the number of shares owned by its largest shareholder, the Korean National Pension Service, has decreased. The holding declined from 32,622,276 shares of common stock, representing 9.20% of 354,687,734 total shares of KB Financial Group as of August 7, 2026, to 32,576,394 shares of common stock, representing 9.18% of 354,687,734 total shares.

The updated shareholding calculation is based on the shareholder registry of KB Financial Group as of September 30, 2026.

View the company filing on SEC.gov

Woodside Energy Group Ltd Reports Q3 2026 Production of 46.2 MMboe and Narrows Full-Year Guidance

2026-10-21T20:48:46Z

Woodside Energy Group Ltd reported quarterly production volumes of 46.2 MMboe (503 Mboe/d) for the third quarter of 2026, representing a 12% increase from the second quarter of 2026. This increase was driven by higher production from Pluto LNG following turnaround and maintenance activities completed in the prior quarter. The company delivered quarterly operating revenue of $4,281 million, up 2% compared to the second quarter of 2026, supported by a realised LNG price of $84/boe, which increased 27% quarter-on-quarter.

Regarding its major growth projects, Woodside Energy Group Ltd reported that the Scarborough Energy Project was 99% complete at the end of the quarter and remains on track for its first LNG cargo this year. The Trion Project reached 71% completion, targeting first oil in 2028, while the Louisiana LNG Project was 32% complete, targeting first LNG in 2029. Additionally, the company entered into an agreement to sell its 70% operated interest in the Calypso Project to bp, and completed a strategic review of Beaumont New Ammonia, initiating a formal process to reduce its investment.

Woodside Energy Group Ltd updated its 2026 full-year production guidance, narrowing the window for Scarborough first LNG cargo and revising Beaumont New Ammonia volumes to 1.5-2.5 MMboe. The revision also reflects reduced production at Okha FPSO and the completion of start-up and performance testing of Julimar Development Phase 3 in September.

View the company filing on SEC.gov

HUTCHMED (China) Limited Closes KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

2026-10-21T20:48:39Z

HUTCHMED (China) Limited announced that the exclusive development and license agreement between its subsidiary, HUTCHMED Limited, and a subsidiary of GSK plc has closed following the completion of customary closing conditions, including antitrust regulatory reviews. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.

The drug candidate, HMPL-A830, is a first-in-class Antibody-Targeted Therapy Conjugate comprising a highly selective and potent Kirsten rat sarcoma small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor antibody. The Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors in China and the US was initiated in September 2026 (clinicaltrials.gov identifier NCT07718581).

Under the terms of the agreement, HUTCHMED Limited is responsible for the global Phase I development program, while the GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities in its territory. Following the closing, HUTCHMED Limited expects to receive a US$110 million upfront payment shortly, and may receive additional development, regulatory and commercial milestone payments of up to a total of US$1.185 billion, as well as tiered royalties on annual net sales.

View the company filing on SEC.gov

Safe & Green Holdings Corp. Enters Equity Purchase Agreement to Acquire IPD Industries and Wildboy Holdings

2026-10-21T20:46:56Z

On October 19, 2026, Safe & Green Holdings Corp., operating as Olenox Industries Inc., entered into an Equity Purchase Agreement to acquire all issued and outstanding equity interests of IPD Industries, Inc. and Wildboy Holdings, Ltd. The total consideration for the transaction is $22.0 million, consisting of 700,000 shares of common stock valued at $1.00 per share, 210,000 shares of Series F Preferred Stock, and $300,000 cash, less certain adjustments. As a result of closing the agreement, the acquired companies are wholly-owned subsidiaries of the issuer.

The acquisitions are intended to advance the strategy of Safe & Green Holdings Corp. to build an integrated gas-to-power-to-compute platform. Located in northeastern British Columbia, the Wildboy assets include a natural gas processing facility with capacity of up to 144 million cubic feet per day and approximately 184,785 acres. According to independent reserve work dated September 30, 2026, the assets contain approximately 56.8 billion cubic feet of proved developed natural gas reserves. Additionally, the acquired IPD platform near Pecos, Texas, holds a 100 MW self-generator registration with the Public Utility Commission of Texas.

View the company filing on SEC.gov

Lufax Holding Ltd to Announce Third Quarter 2026 Financial Results on October 27, 2026

2026-10-21T20:46:49Z

Lufax Holding Ltd announced that it plans to release its third quarter 2026 financial results after the market closes on Tuesday, October 27, 2026, U.S. Eastern Time. The Company’s management will hold an earnings conference call at 9:00 P.M. U.S. Eastern Time on Tuesday, October 27, 2026 (9:00 A.M. Beijing Time on Wednesday, October 28, 2026) to discuss the financial results.

Upon registering, each participant will receive a set of participant dial-in numbers, the event passcode, and a unique access PIN, which can be used to join the conference call.

The replay will be accessible through November 03, 2026, by dialing the following numbers: United States: 1-855-669-9658 International: 1-412-317-0088 Conference ID: 5224502.

Lufax is a leading financial services enabler for small business owners in China. The Company offers financing products designed principally to address the needs of small business owners and others. In doing so, the Company has established relationships with over 85 financial institutions in China as funding partners, many of which have worked with the Company for over three years.

View the company filing on SEC.gov

JinkoSolar Announces Results of 2026 Annual General Meeting

2026-10-21T20:46:43Z

JinkoSolar Holding Co., Ltd. announced that all shareholders resolutions proposed at the Company’s 2026 annual general meeting held today were duly passed. The ordinary resolutions approved by shareholders included the re-election of Mr. Gang Chu as an independent director of the Company and the re-election of Mr. Steven Markscheid as an independent director of the Company. Additionally, shareholders approved the ratification of the appointment of PricewaterhouseCoopers Zhong Tian LLP as auditors of the Company for the fiscal year of 2026 and authorized the directors of the Company to determine the remuneration of the auditors of the Company.

The Company's shareholders also passed special resolutions approving the change of the English name of the Company from “JinkoSolar Holding Co., Ltd.” to “Jinko Holdings Limited”. Furthermore, shareholders approved the adoption of “晶科控股有限公司” as the dual foreign name of the Company.

JinkoSolar Holding Co., Ltd. is a holding company combining clean energy industrial operations and strategic investment in emerging technologies. Its industrial foundation is a controlling interest in Jinko Solar Co., Ltd. (SSE: 688223), a global leader in clean energy technology. The Company makes disciplined strategic investments in renewable energy, advanced materials, artificial intelligence, commercial space and other frontier technologies, drawing on its industrial experience and its ability to identify emerging technologies and bring them to commercial scale.

View the company filing on SEC.gov

Integra LifeSciences Holdings Corporation Reports Third Quarter 2026 Results and $2.1 Billion Debt Refinancing

2026-10-21T20:46:37Z

Integra LifeSciences Holdings Corporation reported third quarter revenues of $411.2 million, which increased 2.3% on a reported basis and 2.5% on an organic basis compared to the prior year. Results included an approximate $7 million revenue impact related to flood damage at the Company’s Cincinnati facility.

The Company reported GAAP net income of $14.9 million, or $0.19 per diluted share, in the third quarter of 2026, compared to GAAP net loss of $(5.4) million, or $(0.07) per diluted share, in the prior year. Adjusted net income for the third quarter of 2026 was $46.4 million, or $0.59 per diluted share, compared to $41.6 million, or $0.54 per diluted share, in the prior year.

On October 19, 2026, the Company completed a $2.1 billion debt refinancing consisting of a $1.65 billion senior secured credit facility and $450 million aggregate principal amount of 9.5% senior secured notes due 2033. The new credit facility consists of a $600 million Term Loan A, a $600 million revolving credit facility, and a $450 million Term Loan B. The Company used the proceeds from the refinancing to repay its existing credit facilities and pay related fees and expenses.

For the full year 2026, the Company expects revenues in the range of $1.634 billion to $1.654 billion representing reported growth of -0.1% to 1.2% and organic growth of -0.3% to 0.9%. The Company expects adjusted earnings per diluted share in the range of $2.30 to $2.40.

View the company filing on SEC.gov

Alterity Therapeutics Limited Announces Revised Remuneration and Employment Terms for CEO Dr David Stamler

2026-10-21T20:46:31Z

Alterity Therapeutics Limited announced that its Board has approved changes to the total remuneration package and terms of employment for Dr David Stamler, the Company's Chief Executive Officer and Managing Director, effective from 15 October 2026. The Board approved these changes following a review of remuneration market comparables and the Company's increasing activities. The Company intends to seek shareholder approval at its upcoming annual general meeting for termination benefits included in the revised package.

Under the revised terms, Dr David Stamler will receive a Base Salary of US$525,000 per annum and a Short Term Incentive of Up to 100% of annualised base salary. The agreement specifies a notice period of 6 months’ notice of termination (or payment in lieu). In the event of termination without cause, Dr Stamler is entitled to a lump sum payment equal to 100% of Dr Stamler's then-current annual base salary and 100% of the associated premiums to continue group medical coverage for 12 months, or until Dr Stamler becomes eligible for comparable coverage through a subsequent employer, whichever is earlier.

The revised agreement also includes change of control provisions. Upon a change of control, 100% of all unvested equity awards will vest immediately prior to the effective date of a change of control, subject to Dr Stamler executing a full release of claims. If Dr Stamler resigns within 90 days of certain events, he will receive severance benefits including a lump sum equal to 1x annual base salary, a lump sum equal to his target bonus or any other bonus for the year in which he resigns, and 100% of the associated premiums to continue group medical coverage for 12 months or until he becomes eligible for comparable coverage through a subsequent employer, whichever is earlier.

View the company filing on SEC.gov

GSK plc Announces US FDA Approval of Hibsago on 20 October 2026

2026-10-21T20:46:24Z

In a Form 6-K filing associated with BlackRock ETF Trust II - iShares Flexible Income Active ETF, GSK plc announced that the US Food and Drug Administration has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface antigen (HBsAg) levels ≤3000 IU/ml, as determined by an FDA-authorised test.

The approval was supported by results from the B-WELL phase III trials showing functional cure rates of 19% in adults with ≤3000 IU/ml HBsAg, compared to current standard of care alone, which typically achieves less than 1% functional cure rate after one year of treatment. Pooled data from the B-Well phase III trials showed that six-month treatment with bepirovirsen achieved a clinically meaningful 19% functional cure response rate, representing 233 of 1,220 vs. 0 of 614 in the placebo group. In a key secondary endpoint, a functional cure rate of 26% was achieved in participants with ≤1000 IU/ml HBsAg level, representing 200 of 768 vs. 0 of 393 in the placebo group.

GSK plc licensed bepirovirsen from Ionis Pharmaceuticals and collaborated with them on its development. The drug is designed as an antisense oligonucleotide to recognise and inhibit the production of the genetic components of the hepatitis B virus. GSK plc continues to advance regulatory submissions for bepirovirsen across multiple geographies with key regulatory decisions anticipated in the coming months.

View the company filing on SEC.gov

Nuburu, Inc. Acquires 70% of Tekne and Receives NYSE American Warning Letter

2026-10-21T20:46:18Z

On October 15, 2026, Nuburu, Inc. and its subsidiary, Nuburu Defense, LLC, entered into the Tekne Implementation Agreement with Tekne S.p.A. and its existing shareholders. Pursuant to the agreement, Nuburu Defense completed the acquisition of 745,759 shares of Tekne, representing an additional approximately 67.1% interest. Together with its previously held approximately 2.9% interest, Nuburu Defense now owns 70% of Tekne. The fixed purchase price is €5,200,000, consisting of €1,200,000 paid on October 15, 2026, and €1,000,000 payable by each of December 31, 2026, January 31, 2027, February 28, 2027 and March 31, 2027.

In addition to the purchase price, the parties agreed to an earn-out of €20,000,000 in cash, with annual payments calculated as 5% of Tekne’s annual revenues for fiscal years 2027 through 2036, subject to a minimum annual payment of €2,000,000 regardless of Tekne’s revenue.

In connection with the reduction of the earn-out from €29,692,000 under a prior agreement to €20,000,000, Nuburu, Inc. and Nuburu Defense agreed to an irrevocable waiver of €29,694,958.28 payable to the company by Tekne, including a €27,693,000 convertible receivable, as a capital contribution to Tekne.

Separately, on October 19, 2026, Nuburu, Inc. received a public warning letter from NYSE Regulation on behalf of NYSE American LLC. The Exchange issued the letter under Section 1009(a)(i) of the NYSE American Company Guide after determining that the company violated Section 401(a), which requires immediate public disclosure of material information. The finding concerns two material events effective September 30, 2026, that the company disclosed on October 6, 2026. NYSE Regulation explicitly stated that any future violation that could lead to a public warning letter under Section 1009 of the Company Guide will instead result in immediate suspension and commencement of delisting proceedings.

View the company filing on SEC.gov

Entravision Communications Corporation Appoints Brian Krzanich and Gary Ferrera to Board, Announces Board Departures

2026-10-21T20:46:12Z

Entravision Communications Corporation announced the appointment of Brian Krzanich and Gary Ferrera to its Board of Directors, effective October 14, 2026. Mr. Ferrera will also join the Board's Audit Committee and has been determined by the Board to qualify as an audit committee financial expert. Mr. Krzanich brings technology and AI experience, having spent 36 years at Intel, including five as Chief Executive Officer, and currently serves as Chief Executive Officer of Cerence. Mr. Ferrera has more than 30 years of global financial leadership experience, including serving as Chief Financial Officer of nine companies.

In addition to the new appointments, Fehmi Zeko advised the Board on October 19, 2026 of his decision to resign from the Board and its Audit Committee, effective as of October 23, 2026, after seven years of service. Gilbert R. Vasquez also advised the Board on October 20, 2026 of his decision not to stand for reelection at the Company's 2027 Annual Meeting of Stockholders. Mr. Vasquez, who has served as a director for 19 years, will continue to serve as a member of the Board and as Chair of its Audit Committee for the remainder of his term. The Company stated that both decisions were solely for personal reasons and did not result from any disagreement with the Company.

View the company filing on SEC.gov

Shinhan Financial Group Co., Ltd. Subsidiary Shinhan Bank Declares KRW 1,000,000,000,000 Interim Cash Dividend

2026-10-21T20:46:03Z

On October 21, 2026, the Board of Directors of Shinhan Bank, a wholly-owned subsidiary of Shinhan Financial Group Co., Ltd., resolved to establish a record date for an interim dividend and to declare an interim cash dividend of KRW 630.67 per common share, representing an aggregate dividend amount of KRW 1,000,000,000,000.

As the sole shareholder of Shinhan Bank, Shinhan Financial Group Co., Ltd. is entitled to receive the entire amount of the interim dividend. The record date is November 5, 2026.

View the company filing on SEC.gov

Shinhan Financial Group Co., Ltd. Reports Largest Shareholder Stake Decreased to 9.26%

2026-10-21T20:42:59Z

Shinhan Financial Group Co., Ltd. reported that the number of common shares owned by its largest shareholder, Korea’s National Pension Service, decreased from 44,370,524 shares of common stock to 43,476,040 shares of common stock. This change represents a decrease in ownership from 9.45% as of July 30, 2026, to 9.26% as of September 30, 2026.

The disclosure is based on the results of the shareholder registry closing as of September 30, 2026.

View the company filing on SEC.gov

PDS Biotechnology Corporation Updates Corporate Presentation Detailing PDS0301 and PDS0101 Programs

2026-10-21T20:42:53Z

PDS Biotechnology Corporation updated its corporate presentation on October 20, 2026, highlighting progress in its drug development programs. Following a September 2026 financing led by Nant Capital, Dr. Patrick Soon-Shiong joined the Board of Directors. The company is currently designing a registrational Phase 3 protocol for PDS0301 in metastatic colorectal cancer (mCRC). Proceeds from the September 2026 financing are intended to advance PDS0301 into late-stage clinical development, with an additional tranche committed upon submission of a registrational Phase 3 protocol to the FDA.

In clinical trials, an NCI-led Phase 2 trial in MSS/pMMR colorectal cancer with liver metastases, PDS0301 + chemotherapy showed a 71.4% objective response rate at six months. More than 380 patients have been dosed across Phase 1 & Phase 2. Five PDS0301 data readouts are anticipated by the company between Q4 2026 and Q2 2028.

For its PDS0101 program, the company reported a 39.3-month median overall survival in the VERSATILE-002 trial evaluating PDS0101 in combination with pembrolizumab for first-line HPV16-positive recurrent/metastatic head and neck cancer. PDS Biotechnology Corporation is currently seeking a strategic partnership or external funding for the further development of PDS0101.

View the company filing on SEC.gov

Vertical Aerospace Ltd. Appoints Marc Fontaine to Board of Directors, Effective October 21, 2026

2026-10-21T20:42:41Z

On October 20, 2026, the Board of Directors of Vertical Aerospace Ltd. appointed Marc Fontaine to serve as a director of the Company, effective October 21, 2026. Mr. Fontaine currently serves as the Chief Executive Officer of Helsing SAS, the French entity of Helsing, and brings more than two decades of experience across aerospace, defence and technology. His appointment was proposed by Mudrick Capital Management L.P. pursuant to its director appointment rights set forth in the Company’s amended and restated memorandum and articles of association.

Prior to joining Helsing, Mr. Fontaine held senior roles across Airbus’s commercial aircraft, defence and space, and helicopter businesses, including serving as Digital Transformation Officer where he led a team of 2,000 and launched Skywise, its aviation data platform. His appointment follows the recent additions of former Airbus Commercial Aircraft CEO Fabrice Brégier as Chair of Vertical’s Board and former Leonardo Helicopters U.S. CEO Clyde Woltman as a director.

Additionally, Vertical Aerospace Ltd. previously retained Jefferies LLC on 24 September 2026 as its financial advisor to assist with a review of strategic alternatives, including potential strategic and financial partnerships. According to Mr. Fontaine, the company's current priority is funding the path to certification and commercialisation of its Valo aircraft, which has c.1,500 pre-orders from customers across four continents.

View the company filing on SEC.gov

ChipMOS TECHNOLOGIES INC. Announces NT$1,237,950 Thousand Equipment Acquisition and NT$58,557 Thousand Disposal

2026-10-21T20:42:35Z

ChipMOS TECHNOLOGIES INC. announced transactions for the acquisition and disposal of machinery equipment and related accessories with trading counterparty K-SHINE ELECTRONIC CORPORATION. The date of occurrence of the event is 2026/03/15~2026/10/21, with approval from the President of the Company on 2026/10/21. K-SHINE ELECTRONIC CORPORATION is not a related party of the company.

The acquisition of machinery equipment and related accessories has a total transaction price of NT$1,237,950 thousand. The disposal of machinery equipment and related accessories has a total transaction price of NT$58,557 thousand, with a projected gain of NT$37,904 thousand. ChipMOS TECHNOLOGIES INC. stated that the concrete purpose of the transactions is for manufacturing purpose. The company decided on the transactions by referring to the market value and negotiating through mutual agreement, and will perform pursuant to the terms and conditions set forth in the purchase orders agreed by both parties.

View the company filing on SEC.gov

Artificial Intelligence Technology Solutions Inc. Reports Q2 FY2027 Revenue of $1,985,604

2026-10-21T20:42:29Z

Artificial Intelligence Technology Solutions Inc. reported its financial results for the fiscal second quarter ended August 31, 2026, with revenue of $1,985,604, representing an increase of 5% from $1,888,749 in the prior-year quarter. Revenue excluding the Company's largest customer reached $1,627,444, up 61% from $1,010,243 in the prior-year quarter. The largest customer accounted for $358,160, or 18% of total revenue, down from 46% in the prior-year quarter, reflecting a more diversified customer base.

The Company reported a gross profit of $1,063,301, or 54% of revenue, which included a $270,987 non-cash inventory write-down related to its discontinued residential camera product line. Excluding this write-down, gross profit was $1,334,288, or 67% of revenue. Loss from operations was $2,680,396 for the quarter, while loss from operations excluding the inventory write-down was $2,409,409.

Artificial Intelligence Technology Solutions Inc. also announced an expansion of its cost-reduction program on October 20, 2026. The Company expects cost and cash savings to exceed $350,000 per month from February 2027. Management targets reaching monthly operating cash breakeven in January 2027 and all-in cash breakeven in the second calendar quarter of 2027.

View the company filing on SEC.gov

Fitch Ratings Affirms Ecopetrol S.A. Global Credit Rating at BB on October 20, 2026

2026-10-21T20:42:23Z

Ecopetrol S.A. announced that Fitch Ratings affirmed the Company’s global credit rating at BB, with a Stable Outlook, and its standalone credit profile (SACP) at‘bbb-’. In addition, Fitch affirmed Ecopetrol’s national long-term and short-term ratings at‘AAA(col)’, with a Stable Outlook, and‘F1+(col)’, respectively.

According to the rating agency, Ecopetrol's standalone credit rating remains within Investment Grade (bbb-), in line with international peers in the sector. Fitch highlighted Ecopetrol's liquidity profile, which is supported by a strong cash position, broad access to capital markets, and an adequate debt maturity structure, and estimated that the Company will not face challenges refinancing its debt obligations maturing in 2027.

Ecopetrol S.A. is the largest company in Colombia, where it is responsible for more than 60% of the hydrocarbon production of most transportation, logistics, and hydrocarbon refining systems. The company also holds leading positions in the petrochemicals and gas distribution segments, and participates in energy transmission and road concessions following its acquisition of 51.4% of ISA’s shares.

At the international level, Ecopetrol S.A. maintains stakes in strategic basins across the American continent, including drilling and exploration operations in the United States, Brazil, and Mexico. Through ISA and its subsidiaries, the company also holds positions in the power transmission business in Brazil, Chile, Peru, and Bolivia, as well as road concessions in Chile and the telecommunications sector.

View the company filing on SEC.gov

Cosan S.A. Announces Expiration of Exclusivity Period for Potential Sale of Rumo S.A. Equity Interest

2026-10-21T20:42:17Z

Cosan S.A. announced that the exclusivity period for negotiations regarding a potential sale of its equity interest in Rumo S.A. has expired without reaching an agreement. The company had engaged in exclusive negotiations with potential investors interested in the equity interest, following proposals received and previously disclosed in a Notice to the Market on June 29, 2026, and a Material Fact on August 20, 2026. The disclosure was made in compliance with Brazilian Securities and Exchange Commission Resolution No. 44/2021.

According to the company, no agreement was reached that it deemed strategically and commercially appropriate for the sale of any portion of its equity interest. Cosan S.A. reiterated that it continues to evaluate alternatives across all of its assets with a view to optimizing its capital structure, while remaining committed to creating value for its shareholders in connection with any such potential transactions.

View the company filing on SEC.gov

Prudential plc Announces Application for Admission of 10,916 Ordinary Shares to Trading on London Stock Exchange

2026-10-21T20:42:05Z

Prudential plc announced that an application has been made to the London Stock Exchange for 10,916 ordinary shares of 5 pence each to be admitted to trading on the main market of the London Stock Exchange. The admission date for the Shares is expected to be 22 October 2026. When issued, these Shares will rank pari passu with the existing ordinary shares.

The Shares will be issued by Prudential plc in connection with the scrip dividend alternative for the 2026 first interim dividend. Prudential has made available a share dealing facility to enable United Kingdom shareholders to participate in the scrip dividend alternative for the 2026 first interim dividend if they cannot provide an address in Hong Kong or details of a Hong Kong qualifying brokerage account. 4,148 of the Shares will be issued by Prudential in connection with this share dealing facility.

Prudential plc provides life and health insurance and asset management in Greater China, ASEAN, India and Africa. The business has dual primary listings on the Stock Exchange of Hong Kong and the London Stock Exchange, as well as a secondary listing on the Singapore Stock Exchange and a listing on the New York Stock Exchange in the form of American Depositary Receipts.

View the company filing on SEC.gov

Banco Santander, S.A. to Disclose First Nine Months of 2026 Results on 28 October 2026

2026-10-21T20:40:19Z

Banco Santander, S.A. has announced that it will disclose its financial results for the first nine months of 2026 on Wednesday, 28 October 2026. The Bank plans to host a presentation for analysts via audio conference at 10:00 a.m. (Madrid time), which can be followed through its corporate website. Additionally, a presentation for the media will be held via audioconference at 12:00 p.m. (Madrid time).

View the company filing on SEC.gov

Warner Bros. Discovery, Inc. Reports Third-Quarter 2026 Results

2026-10-21T20:40:12Z

Warner Bros. Discovery, Inc. reported third-quarter 2026 results. Revenues totaled $32.3 billion, up 5.3% year over year. Diluted EPS from continuing operations was $0.13, which includes a non-cash impairment charge associated with the Company's held-for-sale Mexico wireless business as well as employee separation charges, versus $1.29 in the year-ago quarter, which included a gain recognized on the sale of the DIRECTV investment; adjusted EPS* was $0.65, versus $0.54 in the year-ago quarter. Operating income was $4.1 billion; adjusted operating income* was $7.6 billion.

The company added more than 1 million Advanced Connectivity customers for a second consecutive quarter, driven by net adds across fiber, fixed wireless, and postpaid phone. Advanced Connectivity service revenue was $23.9 billion, up 6.1% year over year, and Advanced Connectivity operating income was $7.6 billion, up 18.9% year over year. The company reached more than 39 million total consumer and business locations with fiber, and remains on track to reach over 40 million total fiber locations by the end of 2026 and more than 60 million locations by the end of 2030.

For its financial outlook, the company increased its outlook for 2026 adjusted EPS and lowered its long-term outlook for capital investment. The updated outlook includes service revenue growth in the low-single-digit range annually, adjusted EPS in the $2.40 range in 2026, and capital investment in the $23 billion to $24 billion range in 2026. Free cash flow is projected to be $18 billion+ in 2026, $19 billion+ in 2027, and $21 billion+ in 2028. Additionally, on October 13, 2026, the company entered into an agreement to sell its Mexico wireless business, recording a non-cash impairment charge of $2.6 billion.

View the company filing on SEC.gov

Northern Trust Corporation Reports Third Quarter 2026 Net Income of $642.9 Million

2026-10-21T20:40:06Z

Northern Trust Corporation reported third quarter net income of $642.9 million, or $3.40 per diluted common share, compared to $792.2 million, or $4.23 in the second quarter of 2026 and $457.6 million, or $2.29 in the third quarter of 2025. Total Revenue (FTE*) was $ 2,302.1 million, representing a decrease of (15) % sequentially but an increase of 13 % compared to $ 2,030.9 million in the prior-year quarter. Noninterest Expense was $ 1,492.5 million, down (9) % sequentially and up 5 % compared to $ 1,422.9 million in the prior-year quarter.

The results for the quarter included notable items totaling a pre-tax impact of $48.7 million to Other Noninterest Income. This impact consisted of a $34.0 million pre-tax gain on the sale of the guardianship services business and a $14.7 million pre-tax incremental gain related to Northern Trust’s participation in the second Visa Exchange Offer.

Total Assets Under Custody/Administration were $ 19,896.6 billion as of September 30, 2026, which is a decrease of (1) % sequentially and an increase of 9 % compared to $ 18,247.6 billion as of September 30, 2025. Total Assets Under Management were $ 1,963.0 billion, representing an increase of 11 % compared to $ 1,772.7 billion in the prior-year quarter.

During the quarter, Northern Trust Corporation returned $514.2 million to common shareholders through dividends and share repurchases. The Corporation declared cash dividends of $161.9 million to common stockholders, increasing its quarterly cash dividend to $0.88 per share from $0.80 per share. It also repurchased 1,901,679 shares of common stock at a total cost of $352.3 million, with an average price per share of $185.27.

View the company filing on SEC.gov

BankUnited, Inc. Reports 3Q 2026 Net Income of $72 million and Diluted EPS of $1.01

2026-10-21T20:37:41Z

BankUnited, Inc. reported net income of $72 million, or $1.01 diluted EPS, for the quarter ended September 30, 2026. Excluding the impact of securities sales, adjusted net income was $74 million, or $1.03 adjusted diluted EPS. Net interest margin expanded to 3.16%, up 10 bps from the prior quarter and up 16 bps from a year ago. Chairman, President and Chief Executive Officer Rajinder Singh noted that deposit momentum and net interest margin expansion ahead of guidance contributed to the solid performance.

Average core loans increased $706 million, or 4%, from a year ago, while total average loans decreased by $314 million from the prior quarter due to purposeful runoff in non-core loans. Ending non-interest demand deposits represented 32.2% of total deposits, down $821 million, or 8%, from the prior quarter primarily due to seasonal normalization. During the quarter, the company repurchased approximately 2.1 million shares for an aggregate of $97.0 million.

Credit quality metrics remained strong, with criticized and classified loans decreasing $176 million, or 14%, from a year ago and decreasing $10 million, or 1%, from the prior quarter. The net charge-offs ratio remained low at 0.11% in both the current and prior quarter, down from 0.25% a year ago. NPLs were down $116 million, or 30%, from a year ago, and up $40 million, or 18%, from the prior quarter.

View the company filing on SEC.gov

Labcorp Holdings Inc. Declares Cash Dividend of $0.72 Per Share

2026-10-21T20:37:35Z

Labcorp Holdings Inc. announced on October 21, 2026, that its Board of Directors has declared a cash dividend in the amount of $0.72 per share of common stock. The dividend will be payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026.

View the company filing on SEC.gov

Healthcare Services Group, Inc. Reports Third Quarter 2026 Results and Raises 2027 Growth Outlook

2026-10-21T20:37:29Z

Healthcare Services Group, Inc. reported its financial results for the three months ended September 30, 2026, with revenue of $479.6 million and net income of $24.9 million, or $0.36 diluted earnings per share. The company reported cash flow from operations of $30.2 million, or $20.7 million when excluding a $9.5 million change in payroll accrual. Based on its performance and outlook, the company raised its 2027 revenue growth expectations from mid single-digits to low double-digits and projected fourth quarter revenue in the range of $535 to $545 million.

On October 6, 2026, Healthcare Services Group, Inc. completed the acquisition of NEXDINE Hospitality for an upfront purchase price of $93.5 million, funded with cash on hand. NEXDINE will operate as a wholly-owned subsidiary, retaining its brand identity and leadership team. The acquisition is expected to contribute over $150 million in annual revenue at comparable margins and be immediately accretive to earnings. Additionally, following the court-approved sale of Genesis to 101 W. State Street on October 14, 2026, in the Genesis Bankruptcy case, the company recorded an estimated recovery of $6.1 million.

Under its February 2026 share repurchase plan to buy back $75.0 million of common stock through January 2027, the company repurchased $11.7 million of common stock during the third quarter. Year to date, the company has repurchased $56.6 million of common stock and has 7.7 million shares remaining under its authorization. As of the end of the third quarter, the company had cash and marketable securities of $204.3 million and an unutilized $300.0 million credit facility.

View the company filing on SEC.gov

Genprex, Inc. Highlights Peer-Reviewed Research on TUSC2 Gene Role in Brain Aging Published October 21, 2026

2026-10-21T20:37:23Z

Genprex, Inc. highlighted new peer-reviewed research identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging. The study, entitled "Mitochondrial calcium sensor TUSC2 protects the aging hippocampus from proteostasis collapse in a sex-specific manner", was published in Mechanisms of Ageing and Development by researchers at Meharry Medical College. TUSC2 is the therapeutic gene used in Genprex's investigational REQORSA® gene therapy, which is being developed for the treatment of cancer.

The research found that loss of TUSC2 in mice was associated with substantial disruption of mitochondrial function, of protein homeostasis, and of pathways involved in neuronal communication within the hippocampus. These effects were markedly more pronounced in male mice than in females, suggesting important sex-specific differences in the biological response to TUSC2 deficiency. Additionally, the researchers analyzed existing human gene-expression datasets and found that TUSC2 expression declined significantly with age in 11 of 13 examined brain regions, with additional reductions observed in Alzheimer's disease datasets.

While the research did not evaluate REQORSA as a treatment for aging or neurodegenerative disease, Genprex stated that the findings expand scientific understanding of the biological functions of TUSC2, the gene underlying the company's lead oncology program. Genprex believes that these findings suggest that TUSC2 may play a foundational role in brain health and further support the importance of understanding how biological functions are disrupted in aging and how restoring TUSC2 may open new avenues for therapeutic intervention in age-related cognitive disorders.

View the company filing on SEC.gov

Stifel Financial Corp. Reports Third Quarter 2026 Net Revenues of $1.43 billion

2026-10-21T20:37:16Z

Stifel Financial Corp. reported its financial results for the three months ended September 30, 2026, with net revenues of $1.43 billion, compared with $1.43 billion in the third quarter of 2025. GAAP net income available to common shareholders was $224.8 million, or $1.40 per diluted common share, compared with $202.1 million, or $1.22 per diluted common share, in the prior-year period. On a non-GAAP basis, net income available to common shareholders was $234.1 million, or $1.46 per diluted common share.

The company's Global Wealth Management segment reported record net revenues of $980.3 million, up 8% from $907.4 million in the third quarter of 2025, driven by higher asset management revenues and net interest income. Pre-tax net income for the segment rose to $374.4 million from $342.7 million in the year-ago quarter. Total client assets reached $576.5 billion, representing a 6% increase over the year-ago quarter, which included $10.2 billion of client assets from the Stifel Independent Advisors business sold on February 2, 2026.

In contrast, the Institutional Group reported net revenues of $430.3 million, down from $500.4 million in the third quarter of 2025. Pre-tax net income for the Institutional Group decreased to $76.3 million from $89.3 million in the prior-year quarter, impacted by lower investment banking revenues and transactional revenues. During the quarter, Stifel Financial Corp. repurchased $124.0 million, or 1.6 million shares, of its outstanding common stock at an average price of $76.95, and announced a strategic investment in Meow Technologies.

View the company filing on SEC.gov

Vivos Therapeutics, Inc. Regains Compliance with Nasdaq Stockholders' Equity Standard

2026-10-21T20:37:11Z

Vivos Therapeutics, Inc. announced that on October 20, 2026, it received a letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC stating that the company complies with the minimum stockholders' equity requirement of Nasdaq Listing Rule 5550(b)(1). This rule requires a listed company to maintain a minimum of $2.5 million in stockholders' equity. The determination was based on the company's Current Report on Form 8-K filed October 19, 2026. Previously, in April 2026, the company received a deficiency notice stating that it did not comply with Nasdaq's continued listing requirements.

The company regained compliance following the closing of its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided co-ownership interest in its pseudohypoxia early-warning test. In connection with the transaction, Vivos Therapeutics, Inc. issued 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12,000,000. The preferred stock is expected to increase stockholders' equity by more than $10 million, subject to final purchase price accounting and review by the company's independent registered public accounting firm.

The letter from the staff further stated that if the company fails to evidence compliance upon the filing of its next periodic report, the company may be subject to delisting. In that case, the staff would provide written notification to the company, which may then appeal the determination to a Nasdaq Hearings Panel.

View the company filing on SEC.gov

RedHill Biopharma Ltd. Regains ex-North America Rights to RHB-102

2026-10-21T20:37:05Z

RedHill Biopharma Ltd. announced that it has regained the ex-North America rights to RHB-102 through a mutual agreement with Hyloris Pharmaceuticals SA for the termination of the License & Development Agreement. Under the mutual agreement, the License Agreement, dated February 24, 2025, was effectively terminated on October 15, 2026, and Hyloris agreed to pay the Company a one-time break-up fee in the amount of $200,000.

The termination of the License Agreement returns to RedHill all ex-North America rights to RHB-102, a once-daily, proprietary, bimodal extended-release oral tablet formulation of ondansetron, a 5-HT3 antagonist. With full worldwide rights to RHB-102, the Company continues its late-stage development for oncology support and GI indications, including GLP-1/GIP-associated GI intolerance, and proceeds with exploring potential partnerships.

View the company filing on SEC.gov

Ashford Hospitality Trust, Inc. Announces Share Purchase Agreement, $17 million Advisory Fee Waiver, and Termination of $100 million ATM Program

2026-10-21T20:26:50Z

Ashford Hospitality Trust, Inc. entered into a Share Purchase Agreement on October 20, 2026, with Ashford Inc., under which Ashford Inc. agreed to purchase, for the quarter ended September 30, 2026 and each calendar quarter ending after that date, a number of shares of common stock equal to 2.5% of the outstanding shares on the last day of that purchase quarter. If Ashford Inc. has not acquired the full quarterly purchase amount within six (6) months after the last day of the applicable purchase quarter, it must provide the company with a credit against advisory fees equal to the number of shortfall shares multiplied by 150% of the VWAP for the period beginning on the day after the last day of that purchase quarter and ending on deadline with respect to such purchase. The agreement terminates automatically upon the earliest of several events, including the third (3rd) anniversary of the effective date, or if the common stock is no longer listed on the NYSE.

Additionally, on October 20, 2026, Ashford Hospitality Trust, Inc., Ashford Hospitality Limited Partnership, and Ashford TRS Corporation entered into a Limited Waiver with Ashford Inc. and Ashford Hospitality Advisors LLC. Under the waiver, Ashford Inc. is waiving the advisory fees that would otherwise be payable during the six (6)-month period ending on April 20, 2027. The waived fees will not accrue or become payable at any time. According to an accompanying press release, the company expects the waiver to save approximately $17 million, or approximately $2.60 per common share.

On the same date, the company terminated its Equity Distribution Agreement, dated as of April 11, 2022, with Virtu Americas LLC, effective as of the close of business on October 20, 2026. Under the agreement, the company was permitted to sell shares of its common stock having an aggregate offering price of up to $100 million. The termination effectively ended the company's at-the-market program.

View the company filing on SEC.gov

William Blair Initiates Coverage of Vor Biopharma at Outperform

2026-10-21T13:58:46Z

Fintel reports that on October 21, 2026, William Blair initiated coverage of Vor Biopharma (NASDAQGS:VOR) with a Outperform recommendation.

Prior to this coverage initiation, on October 20, 2026, the stock closed at $19.03. The market performance of Vor Biopharma leading up to this action shows a one-week price change of -0.16%, measured from a baseline close of $19.06 on October 13, 2026. Over a longer timeframe, the stock experienced a one-month price change of -11.07%, declining from a baseline close of $21.40 on September 18, 2026.

Separately from William Blair's individual rating, the broader analyst consensus for Vor Biopharma presents a positive outlook. As of the current recommendation period ending October 1, 2026, the aggregate consensus consists of 13 recommendations: 5 strong buy, 6 buy, and 2 hold ratings. This distribution represents a positive recommendation rate of 84.6% and a hold rate of 15.4%. Additionally, the current consensus price target mean was recorded at $39.78 as of October 2, 2026, representing an implied change of +109.04% from the stock's pre-action close. The consensus target median stands at $40.80.

Vor Biopharma last reported its quarterly earnings on August 11, 2026. For that period, the company reported an actual earnings per share (EPS) of -1.16, compared to the analyst estimate of -0.7113. Both actual and estimated revenues for the quarter were reported at $0.00. The company's upcoming earnings announcement is scheduled for November 11, 2026.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 21, 2026	William Blair		Outperform	initiated coverage

Abbott Laboratories Reports Third-Quarter 2026 Results

2026-10-21T12:51:08Z

Abbott Laboratories reported net sales of $13,013 million for the third quarter ended Sept. 30, 2026, representing a 14.5 percent increase on a reported basis and 7.0 percent on a comparable basis compared to the third quarter of 2025. Third-quarter GAAP diluted EPS was $0.53, and adjusted diluted EPS was $1.42, which excludes specified items. Net earnings for the quarter were $920 million, down from $1,644 million in the prior year's third quarter.

For the full year 2026, Abbott Laboratories projects comparable sales growth to be approximately 6.0 percent. The company also tightened its full-year 2026 adjusted diluted EPS guidance range to $5.50 to $5.55, reaffirming the midpoint of its previously provided guidance. For the fourth quarter of 2026, the company projects adjusted diluted earnings per share of $1.62 to $1.67.

During the quarter, Abbott Laboratories expanded its portfolio with key new product approvals. In August, the company announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo and received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder. In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ and launched SimpleScreen™ CRC.

View the company filing on SEC.gov

M/I Homes Reports 2026 Third Quarter Results

2026-10-21T12:49:50Z

M/I Homes, Inc. reported its financial results for the three months ended September 30, 2026. The Company reported pre-tax income of $86.9 million and net income of $66.6 million ($2.56 per diluted share). These results include pre-tax inventory charges of $4.7 million ($0.14 per diluted share). This compares to pre-tax income of $139.8 million and net income of $106.5 million, or $3.92 per diluted share, for the third quarter of 2025. Additionally, revenue declined 5% to $1.1 billion during the quarter.

Operational results for the quarter showed that homes delivered in 2026's third quarter decreased 2% to 2,241 homes, compared to 2,296 homes delivered in 2025’s third quarter. New contracts decreased 2% to 1,861 for the third quarter of 2026 compared to 1,908 in last year’s third quarter. Backlog units at September 30, 2026 decreased 7% to 2,046 homes, with an average sales price of $539,000. The Company's cancellation rate was 12% in both the third quarter of 2026 and 2025.

Robert H. Schottenstein, Chief Executive Officer and President, commented that the third quarter results reflect increasingly difficult market conditions, including higher mortgage interest rates, weaker demand and growing economic uncertainty. He noted that the company's financial condition is highlighted by record shareholders’ equity of $3.3 billion, cash of $621 million, and a homebuilding debt to capital ratio of 18%. During the quarter, the company repurchased $50 million of common stock.

View the company filing on SEC.gov

Teledyne Technologies Reports Third Quarter 2026 Net Sales of $1,684.9 million

2026-10-21T12:49:39Z

Teledyne Technologies Incorporated reported third quarter 2026 net sales of $1,684.9 million compared with net sales of $1,539.5 million for the third quarter of 2025, an increase of 9.4%. Net income attributable to Teledyne was $272.8 million ($5.82 diluted earnings per share) for the third quarter of 2026 compared with $220.7 million ($4.65 diluted earnings per share) for the third quarter of 2025. Non-GAAP net income attributable to Teledyne was $315.1 million ($6.72 diluted earnings per share).

Teledyne Technologies Incorporated announced that its management believes full year 2026 GAAP diluted earnings per share will be in the range of $21.71 to $21.87, and fourth quarter 2026 GAAP diluted earnings per share will be in the range of $5.68 to $5.83. Management further believes that full year 2026 non-GAAP diluted earnings per share will be in the range of $25.40 to $25.50, and fourth quarter 2026 non-GAAP diluted earnings per share will be in the range of $6.60 to $6.70.

Teledyne Technologies Incorporated also discussed its pending acquisition of Varex Imaging Corporation. On August 10, 2026, Teledyne and Varex entered into a definitive agreement under which Teledyne will acquire Varex in a cash transaction valued at approximately $1.1 billion, which considers Varex’s outstanding equity awards and net debt. The company plans to fund the pending acquisition from cash on hand as well as available borrowings under its credit facility. The transaction is expected to close in early 2027 and is subject to customary closing conditions, including regulatory approvals and approval by Varex’s stockholders.

View the company filing on SEC.gov

Identiv, Inc. Commences $20 Million Tender Offer and Announces Preliminary Third Quarter 2026 Results

2026-10-21T12:27:55Z

Identiv, Inc., filing as INVE Technologies, Inc., announced on October 21, 2026, that it has commenced a modified "Dutch auction" self-tender offer to purchase for cash up to $20 million in value of shares of its common stock, $0.001 par value per share. The company is offering a price not greater than $3.40 per share nor less than $2.85 per share, net to the seller in cash. The tender offer commenced October 21, 2026, and will expire at 5:00 p.m., New York City time, on Thursday, November 19, 2026, unless extended or terminated. The company will use cash on hand to fund the repurchase of shares in the tender offer and to pay all related fees and expenses.

The company also announced preliminary unaudited financial results for the third quarter ended September 30, 2026. Based on currently available information, the company expects revenue of $ 2.9 to $ 3.1 million, gross margin of 18 % to 19 %, net income of $ 0.4 to $ 0.8 million, and net income per share of $ 0.01 to $ 0.02. Additionally, the company's cash balance as of September 30, 2026, was $87.1 million. These preliminary results reflect the closing of the asset sale transaction with Trackonomy Systems, Inc. on September 15, 2026.

View the company filing on SEC.gov

Worthington Steel Issues Statement Ahead of Kloeckner & Co Extraordinary General Meeting

2026-10-21T12:27:37Z

Worthington Steel, Inc. issued a statement on October 21, 2026, in response to investor inquiries regarding the upcoming extraordinary general meeting of Klöckner & Co SE. The meeting is scheduled to take place as planned on Friday, Oct. 23, 2026, in Düsseldorf, Germany, and will include a vote on the implementation of a domination and profit and loss transfer agreement.

Should the vote on the agreement not achieve the required 75% majority of the capital represented, Worthington Steel, Inc. will not pursue another vote on the implementation of a domination and profit and loss transfer agreement for at least one year from the date of the upcoming meeting. Worthington Steel, Inc. and Kloeckner & Co entered into the agreement on September 8, 2026, which remains subject to shareholder approval and registration with the competent commercial register before becoming effective.

Until the agreement becomes effective, Kloeckner continues to operate independently. Following the effectiveness of the agreement, the expected combined organization is anticipated to employ approximately 12,000 people and operate approximately 150 facilities, primarily in North America, with additional operations in Europe and Asia.

View the company filing on SEC.gov

Baird Downgrades Accenture to Neutral from Outperform

2026-10-21T12:27:36Z

Fintel reports that on October 21, 2026, Baird downgraded their outlook for Accenture (NYSE:ACN) (BIT:1ACN) from Outperform to Neutral.

Prior to this rating action, Baird had maintained an Outperform rating on Accenture on March 20, 2026. Accenture plc is a multinational professional services company headquartered in Dublin, Ireland. It operates primarily in the domain of IT services and consulting, positioning itself as a leader in digital, cloud, and security solutions across a broad range of industries. Its strategy involves leveraging its extensive global network, profound industry expertise, and advancements in areas such as artificial intelligence and machine learning to deliver comprehensive, end-to-end solutions that nurture business growth and operational efficiency.

On October 20, 2026, the day before the rating action, Accenture's stock closed at $239.12. This latest close of $239.12 represents a price change of +11.97% over one week, compared to a baseline close of $213.56 on October 13, 2026. Over a one-month period, the stock experienced a price change of +31.90% from a baseline close of $181.29 on September 18, 2026.

Accenture recently reported its latest earnings on October 1, 2026. The company posted an actual EPS of 3.29, which was above the estimated EPS of 3.2141, representing an EPS surprise of +2.36%. Actual revenue for the period reached $18,679,110,000.00, exceeding the estimated revenue of $18,212,098,486.00.

Separately from Baird's individual rating, the broader analyst consensus target for Accenture was updated on October 2, 2026. The current consensus target mean is $212.20, and the median is $201.45, representing an implied change of -11.26% from the stock's price. This is an increase from the prior consensus target mean of $198.25 recorded on September 15, 2026, reflecting a consensus target revision of +7.04%. As of the current recommendation period starting October 1, 2026, the aggregate analyst recommendations for Accenture consist of 6 strong buy, 12 buy, 14 hold, 0 sell, and 0 strong sell ratings, totaling 32 recommendations. This represents 56.3% positive recommendations and 43.8% hold recommendations. In the prior period starting September 1, 2026, the recommendations consisted of 6 strong buy, 13 buy, 13 hold, 0 sell, and 0 strong sell ratings, representing 59.4% positive recommendations and 40.6% hold recommendations.

Other recent analyst actions on Accenture include Susquehanna maintaining a Neutral rating on October 15, 2026, and TD Cowen maintaining a Hold rating on the same day. On October 6, 2026, Mizuho maintained an Outperform rating. Earlier, on October 2, 2026, Truist Securities maintained a Hold rating, Guggenheim reiterated a Neutral rating, and Evercore ISI Group maintained an Outperform rating.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 21, 2026	Baird	Outperform	Neutral	downgrade
October 15, 2026	Susquehanna	Neutral	Neutral	maintained
October 15, 2026	TD Cowen	Hold	Hold	maintained
October 6, 2026	Mizuho	Outperform	Outperform	maintained
October 2, 2026	Truist Securities	Hold	Hold	maintained
October 2, 2026	Guggenheim	Neutral	Neutral	reiterated
October 2, 2026	Evercore ISI Group	Outperform	Outperform	maintained

CME Group Inc. Reports Highest Q3 Revenue on Record for Q3 2026

2026-10-21T12:27:24Z

CME Group Inc. reported its financial results for the third quarter of 2026, including revenue of $1.7 billion and operating income of $1.1 billion. Net income was $1.0 billion and diluted earnings per common share were $2.89. On an adjusted basis, operating income was $1.2 billion, net income was $1.1 billion and diluted earnings per common share were $3.02.

During the quarter, average daily volume reached a third-quarter record of 29.4 million contracts, and non-U.S. average daily volume reached a third-quarter high of 9 million contracts. Clearing and transaction fees revenue for third-quarter 2026 totaled $1.4 billion, with a total average rate per contract of $0.679. Market data revenue totaled a record $243 million for third-quarter 2026, representing an increase of 20%.

As of September 30, 2026, CME Group Inc. had $2.4 billion in cash, which includes $225 million deposited with Fixed Income Clearing Corporation, and $3.4 billion of debt. The company returned nearly $1 billion to shareholders during the quarter, with $465 million in regular quarterly dividends and $524 million in share repurchases.

CME Group Inc. exchanges offer a range of global benchmark products across major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals.

View the company filing on SEC.gov

Baird Upgrades Northrop Grumman to Outperform from Neutral

2026-10-21T10:41:36Z

Fintel reports that on October 21, 2026, Baird upgraded their outlook for Northrop Grumman (NYSE:NOC) (LSE:0K92) from Neutral to Outperform.

Northrop Grumman Corporation, based in the United States, is a prominent player in the global aerospace and defense industry. The company is extensively involved in the development, manufacture, and provision of advanced systems for defense, aerospace, and security applications. Key projects reflect its comprehensive capabilities in areas including unmanned systems, cyber warfare, and missile defense. Notably, Northrop Grumman is the prime contractor for the U.S. Air Force's B-21 Raider long-range strike bomber and contributes significantly to the F-35 Lightning II program.

On October 20, 2026, the day prior to the rating action, the stock's pre-action close was $534.00. This latest close follows a one-week price change of +10.93% from a baseline close of $481.38 on October 13, 2026. Over a one-month period, the stock recorded a price change of +1.25% from a baseline close of $527.39 on September 18, 2026.

The company reported its latest earnings on October 20, 2026. Northrop Grumman posted an actual EPS of 7.89, which was above the estimated EPS of 7.253, representing an EPS surprise of +8.78%. The actual revenue was $11,122,000,000.00, compared to the estimated revenue of $11,251,757,257.00.

As of October 3, 2026, the current consensus target mean was $659.51, with a median target of $642.60. The current mean target implies a change of +23.50%. This compares to a prior consensus target mean of $663.67 on September 15, 2026, representing a consensus target revision of -0.63%.

For the current recommendation period of October 1, 2026, the aggregate recommendation total was 29, with 6 strong buy, 12 buy, and 11 hold recommendations. This represents 62.1% positive recommendations and 37.9% hold recommendations. In the prior period of September 1, 2026, the total was 28, with 5 strong buy, 12 buy, and 11 hold recommendations, representing 60.7% positive and 39.3% hold recommendations.

Other recent analyst actions include Bernstein maintaining a Market Perform rating on October 14, 2026. On October 9, 2026, TD Cowen maintained a Hold rating, and Barclays initiated coverage with an Underweight rating. Rothschild & Co initiated coverage with a Buy rating on October 6, 2026. RBC Capital downgraded the stock from Outperform to Sector Perform on October 2, 2026, following a maintained Market Perform rating by Bernstein on September 23, 2026.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 21, 2026	Baird	Neutral	Outperform	upgrade
October 14, 2026	Bernstein	Market Perform	Market Perform	maintained
October 9, 2026	TD Cowen	Hold	Hold	maintained
October 9, 2026	Barclays		Underweight	initiated coverage
October 6, 2026	Rothschild & Co		Buy	initiated coverage
October 2, 2026	RBC Capital	Outperform	Sector Perform	downgrade
September 23, 2026	Bernstein	Market Perform	Market Perform	maintained

Raymond James Initiates Coverage of News at Outperform

2026-10-21T09:14:46Z

Fintel reports that on October 20, 2026, Raymond James initiated coverage of News (NASDAQGS:NWS) (LSE:0K7V) with a Outperform recommendation.

News Corporation, based in the United States, operates globally as a diversified media and information services company. It is a prominent player in the publishing and digital real estate services industries, among others. The company's portfolio encompasses a broad range of media, including book publishing, digital and print news, and subscription video services. Key projects and assets include prominent names such as The Wall Street Journal, HarperCollins Publishers, and Realtor.com.

Prior to the coverage initiation, the stock closed at $32.90 on October 19, 2026. On October 20, 2026, the latest close was recorded at $33.40. Over a one-week period, the stock experienced a price change of +2.52% from a baseline close of $32.58 on October 13, 2026. Over a one-month period, the price change was +2.20% from a baseline close of $32.68 on September 18, 2026.

Separately from the rating by Raymond James, aggregate consensus target data provides further context. As of October 3, 2026, the current consensus target mean was $40.32, and the current consensus target median was $39.35. This mean target represents an implied change of +20.71%. The current mean target is a revision of -0.10% from the prior consensus target mean of $40.36 recorded on September 15, 2026.

In terms of aggregate analyst recommendations, the current recommendation period of October 1, 2026, shows a total of 15 recommendations. This total consists of 4 strong buy, 9 buy, 2 hold, 0 sell, and 0 strong sell ratings, representing 86.7% positive, 13.3% hold, and 0.0% negative recommendations. In the prior recommendation period of September 1, 2026, the total of 15 recommendations consisted of 5 strong buy, 9 buy, 1 hold, 0 sell, and 0 strong sell ratings, representing 93.3% positive, 6.7% hold, and 0.0% negative recommendations.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 20, 2026	Raymond James		Outperform	initiated coverage

Credo Beat, Raised and Fell 20%. The Market Got the Wrong Message.

2026-10-21T06:08:48Z

Here is a puzzle for growth investors. On 1 September, Credo Technology reported its seventh straight quarter of triple-digit revenue growth, beat the top of its own guidance, lifted its full-year outlook and showed the first revenue from a newly acquired silicon photonics business. The next day the stock fell 20%.

Credo sells the high-speed plumbing inside AI data centres: Active Electrical Cables (AECs), optical DSPs, silicon photonics PICs, ZeroFlap optical transceivers and retimers. Its customers are mostly US hyperscalers, plus a growing list of neoclouds. Fintel reiterated its BUY rating after the print, and the argument for buying the dip is a straightforward one.

A clean beat and a real raise

Revenue of US$479.0M rose 115% year on year and 9.6% on the prior quarter, clearing the US$465M to US$475M guidance range. Non-GAAP gross margin held at 68.0% and non-GAAP EPS of US$1.20 rose 131%. Management lifted FY27 revenue growth guidance to more than 85% (from more than 80%), held the optical revenue target at more than US$600M and guided Q2 revenue to US$525M to US$535M, roughly 11% sequential growth at the midpoint.

So why the 20% drop? Three things. The market had hoped for a bigger optical raise. Operating expenses ran ahead of plan as Credo hired for optics R&D. And GAAP gross margin fell 370bp to 64.5% because of purchase accounting from the DustPhotonics acquisition (US$11.0M of amortisation and US$5.7M of share-based compensation in cost of revenue). None of that changes the economics: non-GAAP gross margin barely moved, and the full-year number went up.

The second half is already mapped

Since the print, management has framed Q3 at roughly 20% sequential growth and Q4 at roughly 30%. On Fintel's arithmetic that is about US$636M and US$827M, which lands FY27 near US$2.47B. That is a back-loaded year, but Credo has cleared this kind of bar before: Q3 FY26 was guided to US$340M and came in at US$407M on turns orders from its largest customer.

Optics becomes the second engine

AECs remain the largest business, and 800G demand should persist through FY27 as copper replaces short-reach optics on reliability and power, with first 1.6T AEC revenue arriving in the second half. But the bigger story is optics. Optical DSPs hit a record, ZeroFlap Optics is in production, and the first silicon photonics revenue arrived from DustPhotonics. The US$600M+ optical target splits across three product lines of more than US$100M each. At ZeroFlap ASPs of US$400 to US$600 and exit capacity of 200,000 to 300,000 units a month (rising two to three times into FY28), Fintel does not see the plan as capacity constrained.

Further out, FY28 options keep stacking up. Active LED Cables reach up to 30 metres (against about 7 metres for AECs) with roughly 75% less cable volume, and debut at the OCP Global Summit in October. OmniConnect memory fan-out carries US$2,000 to US$3,000 of content per accelerator, with its pilot customer planning a rack ramp in the second half of CY27, which Fintel thinks could be a US$1B+ opportunity.

"Our portfolio now spans connectivity from millimeters to kilometers, with solutions across optics and copper." (Bill Brennan, CEO, 1 September 2026)

What the Fintel quant data says

The trailing numbers on Credo's Fintel profile show just how quickly the earnings base has moved. TTM revenue rose from US$164M in January 2024 to US$1,591M in August 2026, nearly tenfold. TTM operating income swung from a US$46M loss to US$505M profit, and TTM ROE climbed to 69% from 10% a year earlier, with ROIC at 23% (from 7%).

Fund sentiment82.9
Analyst sent.77.8
Quality72.5
Momentum66.5
Growth49.8
Value37.4
Insider sent.20.6

The standout is Fund Sentiment at 82.9. Institutional ownership filings show 1,011 holders increased positions against 451 sellers, with 421 new holders arriving, during the drawdown. In other words, funds were buying the sell-off rather than running from it. Quality (72.5) confirms the margin profile, while the middling Growth score (49.8) is backward looking: it measures a base that has already compounded.

Positioning is not stretched either. Short interest sits at a moderate 5.0% of float, covering in 1.2 days, and the put/call open-interest ratio of 0.96 is balanced. Implied volatility of 78.9% does signal big moves around the December print. The weak insider scores reflect routine selling rather than anything fundamental.

CRDO factor scores Institutional ownership Short interest

Valuation: the headline multiple overstates it

On TTM GAAP EPS of US$2.83, Credo trades at 77x, which looks expensive. But FY27 non-GAAP EPS implied by guidance is about US$6.20 (35x), and FY28 consensus of roughly US$9.50 puts the stock at about 23x, well below its historical median in the 60s. The shares have recovered about 45% from their mid-September low but remain 29% below the 52-week high of US$308.67.

What could go wrong

Second-half execution. FY27 needs roughly US$1.46B in Q3 and Q4 against US$1.01B in the first half. A Q3 guide well short of ~US$636M would put the 85% floor at risk.
Customer concentration. Four customers are 84% of revenue and the top two are 61%. They order in bursts, so quarters are lumpy.
Copper to optics transition. AEC growth could slow before optical revenue fully replaces it.
GAAP earnings quality. Share-based compensation was 18% of revenue, and goodwill and intangibles are now US$1.37B after DustPhotonics.

The verdict: BUY

The sell-off priced the absence of an optical raise and a messier GAAP line, not a weaker business. The second half is now a defined test, and FY28 adds 1.6T AECs, Active LED Cables, OmniConnect and near-package optics on top of a full optical year. At about 23x FY28 consensus earnings, Fintel thinks the risk/reward favours holding. Next checkpoints: the OCP demo (12 to 15 October) and the Q3 guide in early December.

Eaton's Backlog Just Grew 43%. The Margin Dip Is Now the Easy Comparison.

2026-10-21T06:08:43Z

Eaton is not a cheap stock, and nobody is pretending otherwise. At 32.3x the midpoint of 2026 guidance, the Dublin-domiciled power management group trades at a premium. Fintel has nonetheless initiated coverage with a BUY, on the view that earnings should run ahead of consensus through 2027.

Eaton's Electrical Americas and Electrical Global segments supply switchgear, breakers, UPS, power distribution and (since March) liquid cooling to data centre, utility, commercial and industrial customers.

The quarter that settled the debate

The 2Q26 print on 31 July answered the main worry of the past year. Sales rose 21% to a record US$8.5B on 14% organic growth, against consensus near US$8.16B. Adjusted EPS of US$3.15 beat the US$3.07 forecast. Segment margins of 23.1% landed above the top of guidance, and Electrical Americas margins recovered 190bp sequentially to 27.5%. Management raised 2026 organic growth guidance to 11% to 13% and adjusted EPS to US$13.40 to US$13.60. In mid-September, CEO Paulo Ruiz said July and August were very strong and that Eaton was aiming at the high end of both third-quarter and full-year guidance.

"Just think about this 300 GW of announcements versus the 50 GW that was built over decades." (Paulo Ruiz, CEO, 31 July 2026)

Demand is broad and still accelerating

Rolling 12-month orders rose 41% in Electrical Americas, 33% in Electrical Global and 17% in Aerospace. Electrical backlog is up 43% with a book-to-bill of 1.2. Data centre orders rose about 85%, and the negotiation pipeline more than 130%. Importantly, about 68% of Electrical Americas revenue sits outside data centres, spread across commercial, utility, industrial and residential markets.

The margin floor has been reset

The 2H25/1H26 margin dip came from ramping new capacity and integrating Fibrebond and Boyd Thermal. 3Q26 guidance calls for segment margins of 24.6% to 25.0%, and street work counts 18 of 24 new facilities already ramped. Those ramp costs now become the easy comparison for 2027. Electrical Americas margin of 27.5% is still below the 29.5% of 2Q25, which is the comp opportunity.

The portfolio also upgrades itself in 1Q27. Mobility (13.0% margin, organic sales down 2%) moves to Dana via a Reverse Morris Trust, bringing US$1.1B of cash to Eaton. Excluding Mobility, 2Q segment margin was 24.3%. The €810M COL Group purchase adds European medium-voltage capacity.

What the Fintel quant data says

Eaton's Fintel factor profile leans firmly toward growth and momentum, which fits the thesis.

Momentum75.8
Growth75.5
Quality63.9
Fund sentiment59.9
Analyst sent.58.3
Insider sent.54.9
Value48.2

Red marker = universe average of 50. Piotroski F-score 6.

Momentum (75.8) and Growth (75.5) both sit well above the universe average, backed by Fintel's trailing data: TTM revenue rose 53% from US$19.6B (December 2021) to US$30.0B, and operating income more than doubled from US$2.5B to US$5.5B, with operating margin widening from 13% to 19%. Fintel's history also shows no miss larger than one cent in the last ten quarters.

The near-average Value score (48.2) is honest about the premium. On TTM GAAP EPS of US$9.82, ETN trades at 44.4x, near the top of its five-year range, because Boyd-related amortisation and interest have entered the GAAP line. On the adjusted basis the street uses, it is 32.3x 2026 and 27.3x 2027. Short interest is light at 2.0% of float (5.4 days to cover), so the stock is not leaning on a squeeze, while the 1.31 put/call ratio shows options traders are more cautious. Fund Sentiment of 59.9 confirms institutions are accumulating.

ETN factor scores Institutional ownership Short interest

Where the street sits

Seven of eight recent broker views are positive and one is neutral. Price targets range from US$403 to US$525 (average about US$487). 2027 adjusted EPS estimates range from US$15.39 to US$16.35. Even the neutral view models 18% EPS CAGR over FY26 to FY30; it objects only to the multiple.

What could go wrong

The multiple prices a long cycle. Any pause in data centre orders would hit a stock priced for duration.
Leverage. Net debt roughly doubled to ~US$19.9B after Boyd; goodwill and intangibles of US$32.8B exceed equity of US$20.3B.
Mobility dilution. Street estimates put the annual EPS impact of the Dana deal at ~US$0.70.
Inputs and integration. Copper is up ~29% and steel ~50%; Boyd, Ultra PCS and Fibrebond are all being absorbed at once.

The verdict: BUY

Eaton enters 2027 with record backlog, most of its capacity ramp behind it, pricing that is holding and a portfolio losing its lowest-margin segment. Those are the conditions for earnings to beat a consensus that still models deceleration. Fintel accepts the premium. The 3 November 3Q26 print (guided to US$3.46 to US$3.56) is the first test of whether high-end commentary becomes a higher range.

Enova Lost a Bank Deal and US$1.33B in a Day. It Kept Every Number That Matters.

2026-10-21T06:08:37Z

On 14 September, Enova International withdrew its bank regulatory applications for the US$369M Grasshopper Bancorp acquisition after a coalition of state attorneys general opposed the deal. The next day the shares fell 23.5%, from $226.72 to $173.39. That wiped out roughly $1.33B of market value, or 3.6 times what Enova had agreed to pay for the bank.

Enova is a US online lender to consumers and small businesses that underwrites with machine learning, operating the OnDeck small-business brand and NetCredit consumer brand. Fintel has re-initiated coverage with a BUY, arguing the market has confused a capped long-term multiple with a damaged earnings base.

Guidance was reaffirmed the same day the deal ended

In the very release announcing the withdrawal, management reaffirmed full-year 2026 guidance of 20% to 25% revenue growth and 30% to 35% adjusted EPS growth, guided 3Q26 to about 25% revenue and 30% EPS growth, and said it would accelerate share repurchases. Crucially, Grasshopper had never been in the 2026 numbers. Its value sat in 2027 and beyond (management had sized it at more than 25% EPS accretion at full synergies). The sell-off repriced the near-term base as well.

The quarter before the headline was clean

2Q26 revenue rose 22% to US$929M, ahead of consensus of US$909.6M. Adjusted EPS rose 33% to US$4.31 against US$3.96 expected. Originations of nearly US$2.3B grew 27%, the 11th consecutive quarter of 20%+ growth, and combined receivables hit a record US$5.5B (up 28%). Small business is carrying the growth: segment revenue rose 35% to US$439M on a US$3.8B book that is now 69% of the portfolio.

Metric	2Q26	2Q25	Change
Total revenue	US$929M	US$764M	+22%
Net revenue margin	61%	58%	+3pt
Net charge-off ratio	7.3%	8.1%	(0.8pt)
Adjusted EPS	US$4.31	US$3.23	+33%
Cost of funds	8.1%	8.8%	(0.7pt)

Credit is improving while the book grows

This is the part bears tend to skip. The consolidated net charge-off ratio fell to 7.3% from 8.1%, with consumer charge-offs down 170bp to 12.8% and small business steady at 4.8%. Delinquencies held at 7.5%. Meanwhile funding keeps getting cheaper without deposits: after the withdrawal, OnDeck priced a US$500M small-business ABS at a 6.22% weighted coupon, with AA-rated Class A notes at 5.61%. There are no recourse debt maturities until December 2028.

The buyback is now large relative to the float

Enova has US$218M of covenant capacity and a US$349M authorisation running to June 2027. At US$172.89, US$218M retires about 1.26M shares, roughly 5% of the 24.9M outstanding, at a ~10% earnings yield. Capital earmarked for the bank deal is now free.

What the Fintel quant data says

The Fintel valuation series makes the reset obvious. Fintel's June 2026 print showed a trailing P/E of 18.35x, P/Book of 4.27x and P/TBV of 5.35x, all calculated at a pre-sell-off price of roughly US$247. Applying the same per-share data to the current price gives about 12.8x trailing earnings, 3.0x book and 3.7x tangible book. The trailing multiple is back where it sat through 2025, yet TTM diluted EPS has risen 81% since December 2024 (from US$5.49 in December 2023 to US$13.46 now, rising in each of the last nine periods).

Metric	Fintel Jun-26	At US$172.89*	Dec-24
Trailing P/E	18.35x	12.8x	14.07x
P/Book	4.27x	~3.0x	2.16x
P/TBV	5.35x	~3.7x	2.87x

* Fintel calculation.

Smart money did not flee. Institutional filings show 378 buyers against 303 sellers and a net 1.04M shares added, even as reported value fell US$69.1M. Holders were adding shares while the price fell. Fintel's Fund Sentiment Score is 65.82, above the universe average of 50, and institutional options exposure is call skewed at a 2.13x call/put value ratio. The register is not crowded either: the top ten holders own 36.1% of disclosed shares. Returns have improved in step, with TTM ROE rising from 14% (June 2024) to 27%.

ENVA factor scores Institutional ownership Short interest

What could go wrong

Credit turns with the macro. Consumer charge-offs run at 12.8% on non-prime borrowers; higher yields or energy costs could lift delinquencies with a lag.
Funding costs without deposits. Every 100bp on a US$5.5B book is roughly US$55M of annual pre-tax cost.
Regulatory exposure. The same state AG scrutiny could fall on bank partnerships, rate caps or federal rules.
Growth ceiling and insider selling. State-by-state licensing caps NetCredit; insiders sold about US$15M over the prior quarter.

The verdict: BUY

Enova has always been a nonbank, and a charter was never in the 2026 guidance. What remains is a lender compounding adjusted EPS at 30%+, with improving credit, falling funding costs and meaningful buyback firepower at about 10x forward earnings. Sell-side targets were cut but remain well above the price (Stephens US$205, Citizens US$215, TD Cowen US$220). The late-October 3Q26 print (guided to around US$4.37 adjusted EPS) is the first test.

ENVA on Fintel

Alibaba Just Raised Its AI Ambition by a Third. The Shares Are Down 44%.

2026-10-21T06:08:31Z

Alibaba Cloud's Apsara Conference in Hangzhou (22 to 24 September) delivered one new number that matters: capacity. Alibaba Cloud now targets more than 20GW of operated data centre capacity globally by 2032, against about 2GW in 2022. Last year's plan for a tenfold increase implied roughly 15GW, so the ambition has grown by about a third. Fintel Capital reiterated its BUY.

Alibaba runs China's largest e-commerce platforms (Taobao and Tmall), instant commerce, international marketplaces and Alibaba Cloud, the country's largest public cloud and home of the Qwen models and T-Head chips.

Chips on an annual cadence

T-Head launched the Zhenwu V900 with three times the performance of the M890, 216GB of HBM, 1,200GB/s inter-chip bandwidth and FP8/FP4 support, with single clusters scaling to 500,000 accelerators. Mass production starts in 1Q27, with the J900 following in 3Q28. The silicon stack is now complete across GPUs, CPUs, smart NICs, interconnect and SSD controllers. Fintel thinks T-Head could go from about 10% of cloud compute today to about 50% in the medium term, lowering cost per GW and securing supply that export controls would otherwise cap.

Qwen keeps scaling, and improves itself

Qwen went from 72 billion to 2.4 trillion parameters in two years. Qwen 4 is in training, with the 4.5 and 5 series planned at 5 to 10 trillion. Qwen3.8-Max ran 33 self-improvement cycles without human input and, within two months of launch, generated 8.5 times the revenue and 12 times the tokens of Qwen 3.7. New products (AgentCore, Agent Sandbox, QwenWork and the Qoder CLI, which has served more than 8M developers) move the cloud from renting compute toward running agents for enterprises, which should raise stickiness.

Demand looks strong enough to carry the spend

Cloud revenue grew 45% year on year in the June quarter to RMB48.4B, and segment adjusted EBITA margin rose to 11.6% from 9% in March. Fintel expects growth near 50% in the September quarter. At US$10B to US$15B of revenue per GW, 20GW could support US$200B to US$300B of annual cloud revenue by 2032, comfortably ahead of the company's US$100B guide for FY3/31.

The cost: heavier capex

Getting from roughly 5GW today to 20GW means adding about 2.5GW a year, or at least RMB250B of annual investment (some via leasing and partners). Fintel lifts capex to RMB228B in FY28 and RMB259B in FY29, expects free cash flow to stay negative until FY29 and has trimmed FY27 to FY29 EPS by about 4% for dilution from the recent equity raise.

RMB M	FY26A	FY27E	FY28E	FY29E
Revenue	1,023,670	1,127,396	1,288,253	1,449,484
Adj. net profit	60,658	96,693	139,207	174,276
Adj. EPS (RMB/ADS)	26.12	41.79	60.69	76.30
P/E	28.4x	17.8x	12.2x	9.7x

FY27E onward are Fintel estimates.

What the Fintel quant data says

The most striking signal on Alibaba's Fintel factor profile is Analyst Sentiment at 89.2, far above the universe average. The professionals who model the business most closely are near unanimous.

Analyst sent.89.2
Quality56.9
Growth51.2
Insider sent.49.1
Fund sentiment47.2
Momentum45.9

That contrasts with below-average Fund Sentiment (47.2) and Momentum (45.9) after a 44% fall over the year. When analysts are this positive and institutional positioning still lags, the gap is the opportunity: if the cloud ramp shows up in the November print, there is room for funds to catch up.

Fintel's trailing data explains the hesitation. TTM operating income fell from a RMB152B peak in March 2025 to RMB48B as Alibaba funded instant commerce and AI, and TTM diluted EPS dropped to RMB29.76 per ADS from RMB61.74. Gross margin, however, has held near 40%, so the squeeze sits below gross profit. Cash return on invested capital has been negative (at (1%)) as capex outran cash generation. Options lean bullish, with a put/call open-interest ratio of 0.51, and short interest of 41.0M ADS covers in 6.4 days. The shares also yield 2.88%.

BABA factor scores Institutional ownership Short interest

What could go wrong

Capex and free cash flow. If utilisation or pricing lags, depreciation lands before revenue.
Funding and dilution. Debt adds interest; further equity would extend the ~4% EPS dilution.
Chip execution. V900 mass production could slip; export controls and foundry access constrain supply.
Price wars. Domestic model providers keep cutting token prices, and commerce competition pressures the cash that funds the cloud.

The verdict: BUY

Apsara 2026 delivered a larger, dated capacity target, a chip roadmap with volume dates and products that push the cloud toward running agents. With cloud growth heading toward 50%, margins expanding and the shares at about 18x FY27E and 12x FY28E earnings after a 44% fall, QuantSoft thinks the risk/reward favours holding. Watch the mid-November results (cloud growth and the updated capex range) and V900 volume in 1Q27.

SHEIN Is Down 37% Since Its IPO. The Platform Underneath Is Still Growing.

2026-10-21T06:08:26Z

SHEIN listed on the Hong Kong Exchange on 1 September at HK$48.56, raising about US$1.7B at a valuation near US$26B, roughly a quarter of its private peak near US$100B. A month later it closed at HK$30.84, down 36.5% from the offer price. Fintel Capital has initiated with a SPECULATIVE BUY, arguing the market is pricing a cost shock rather than a demand problem.

The Singapore-headquartered online retailer combines its own on-demand apparel brands with a third-party marketplace across roughly 160 markets.

Why the stock slid

The first interim results on 28 September were ugly on the surface. H1 net revenue rose just 1.0% to US$20.13B, and adjusted net profit fell 55.6% to US$499M. The end of the US de minimis exemption, EU customs changes and a spike in oil and freight costs (linked to Middle East tensions) hit the cost base, and management chose to absorb those costs to protect prices and order momentum. Q2 adjusted net margin fell to 2.1% from 6.2%, with fulfilment expenses up 18.1%.

Demand is holding; the top line hides it

Look underneath and the picture changes. H1 orders rose 6.4% to 549M and Q2 orders rose 7.6% to 298M. LTM active customers grew to 291M from 254M. The reason revenue lags orders is mix: marketplace sales book only commission, so as the marketplace grows, reported revenue understates activity. Service revenue rose 44.2% in Q2 to reach 12.7% of net revenue, and FY25 third-party revenue of US$4.74B was 5.4 times its level two years earlier.

Geography helps too. Q2 revenue outside the US and Europe rose 21.6% to US$4.8B on localised marketplace rollouts in Latin America and the Middle East, now about 43% of revenue. US revenue is still falling but the Q2 decline (6.1%) was narrower than Q1.

"Shein's Hong Kong listing marks a new starting point." (Leigh Gui, CFO, 1 September 2026)

A supply chain that is hard to copy

SHEIN launches styles in batches of 100 to 200 units and reorders winners in about five days. Founder Securities cites 36-day inventory turnover against 90 to 130 days for peers, on around 7,500 contract manufacturers and 72 warehouses. In Fintel's view this lets SHEIN absorb tariffs longer than smaller cross-border sellers.

What the Fintel quant data says

With just one month of trading, SHEIN's Fintel profile is still filling out, so it is worth reading only the fields that reconcile. Fintel scores SHEIN at 57.07 on Growth, above the universe average of 50, consistent with order and marketplace momentum.

Growth57.07

The trailing series show revenue up 31% from US$32.1B (FY23) to US$42.0B (TTM June 2026), although growth has flattened since FY25. TTM operating income fell to US$1.15B from US$1.71B in FY25 as freight and tariffs landed, which is exactly the margin trough the bull case says is cyclical. TTM net income of US$3.28B is flattered by a non-cash gain on preferred shares, which is why diluted EPS (US$0.26) sits far below basic EPS (US$1.28).

The eye-catching number is a 25.19% borrow rate. That reads less like a crowded short and more like a function of the tiny 2.3% tradable float, and it is a reminder of why this is rated speculative.

SHEIN on Fintel

The float roadmap brings buyers

SHEIN joined the Hang Seng Composite Index on 15 September. The 28 February 2027 lock-up expiry lifts free float to 40.4%, which (per Shenton Research) opens Southbound Connect (estimated 31 March 2027) and MSCI China inclusion (base case at the May 2027 review). Near-term supply, in other words, is also the gate to new structural demand.

Valuation

At about US$16.8B, the equity is valued close to company-reported cash resources of US$15.2B (Fintel has not netted merchant payables against that figure). All three sell-side initiations reviewed are positive, with targets 53% to 62% above the current price, and 2027E net profit forecasts of US$1.8B to US$2.1B put the stock at 8 to 9 times.

What could go wrong

Tariffs and customs. EU fees on low-value parcels add costs from November.
Freight and oil. Persistent Middle East disruption would delay margin recovery.
Lock-up overhang. 1,618.0M shares unlock on 28 February 2027, 38.1% of shares and 163 times average daily volume.
Competition, ESG and governance. Temu, AliExpress and TikTok Shop; labour and IP scrutiny; a weighted voting structure with founders holding 59.6%.

The verdict: SPECULATIVE BUY

SHEIN enters 2027 with orders still growing, a marketplace compounding at 40%+, a rest-of-world franchise growing above 20% and a cost base hit by freight and tariffs rather than lost customers. One month of trading, a 2.3% float and the February unlock make the path volatile, and Fintel sets no target. Black Friday trading and the December index reviews are the first tests.

BTIG Upgrades American Electric Power to Buy from Neutral

2026-10-21T00:25:43Z

Fintel reports that on October 20, 2026, BTIG upgraded their outlook for American Electric Power (NASDAQGS:AEP) (WBAG:AEPC) from Neutral to Buy. This rating action occurred on October 20, 2026. On the day prior to this action, October 19, 2026, the stock closed at $124.72. On the day of the rating action, October 20, 2026, the stock closed at $127.26.

American Electric Power Company, Inc. (AEP), based in the United States, is a major player in the energy sector, primarily engaged in the generation, transmission, and distribution of electricity. As one of the largest electric energy companies in the U.S., AEP serves over five million customers across 11 states. The company's vast infrastructure includes approximately 26,000 megawatts of generating capacity and a network of nearly 40,000 miles of electricity transmission lines. Looking at recent market performance, the stock experienced a price change of +1.28% over one week, relative to a baseline close of $125.65 on October 13, 2026. Over a one-month period, the price change was +6.05% from a baseline close of $120.00 on September 18, 2026.

Separately from BTIG's individual rating, aggregate consensus data shows a target mean of $145.93 and a target median of $146.70 as of October 2, 2026, representing an implied change of +14.67%. This is a revision from the prior consensus target mean of $147.25 recorded on September 14, 2026, which is a consensus target revision of -0.89%. In terms of broader analyst recommendations, the current recommendation period as of September 1, 2026, includes 6 strong buy, 10 buy, 12 hold, 0 sell, and 0 strong sell recommendations, totaling 28 recommendations. This represents 57.1% positive, 42.9% hold, and 0.0% negative recommendations. In the prior period as of August 1, 2026, there were 6 strong buy, 9 buy, 14 hold, 0 sell, and 0 strong sell recommendations, totaling 29 recommendations, which represented 51.7% positive, 48.3% hold, and 0.0% negative recommendations.

AEP reported its latest earnings on July 30, 2026, with an actual EPS of 1.36 compared to an estimated EPS of 1.5103, representing an EPS surprise of -9.95%. Actual revenue was $5,445,000,000.00, compared to estimated revenue of $5,394,764,813.00. The company's upcoming earnings date is scheduled for October 28, 2026, during the before market open session. Other recent analyst actions include BMO Capital maintaining a Market Perform rating on October 19, 2026, and JP Morgan maintaining a Neutral rating on the same day. Keybanc upgraded the stock from Sector Weight to Overweight on October 13, 2026, while Barclays maintained an Equal-Weight rating on October 12, 2026.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 20, 2026	BTIG	Neutral	Buy	upgrade
October 19, 2026	BMO Capital	Market Perform	Market Perform	maintained
October 19, 2026	JP Morgan	Neutral	Neutral	maintained
October 13, 2026	Keybanc	Sector Weight	Overweight	upgrade
October 12, 2026	Barclays	Equal-Weight	Equal-Weight	maintained

TD Cowen Upgrades BlackRock to Buy from Hold

2026-10-20T23:54:05Z

Fintel reports that on October 20, 2026, TD Cowen upgraded their outlook for BlackRock (NYSE:BLK) (LSE:0QZZ) from Hold to Buy. This rating action follows a prior action on October 12, 2026, when TD Cowen maintained its Hold rating on the stock. On the day of the upgrade, October 20, 2026, BlackRock shares closed at $1,128.68, compared to the pre-action close of $1,124.60 on October 19, 2026.

BlackRock, Inc., headquartered in the United States, is a premier global asset management firm and a major player in the financial services industry. As the world's largest asset manager, BlackWarrior oversees trillions in assets, including a significant amount of assets under management across a wide array of public and private investment vehicles. Key initiatives and projects for BlackRock include expanding its sustainable investment offerings, leveraging advanced technology like Aladdin in investment management processes, and innovating in areas such as digital asset investment and infrastructure. The stock has experienced positive momentum, with a price change of +5.87% over one week from a baseline close of $1,066.12 on October 13, 2026, and a price change of +5.51% over one month from a baseline close of $1,069.78 on September 18, 2026.

The company recently reported its latest earnings on October 14, 2026. BlackRock posted an actual EPS of 15.93, which exceeded the estimated EPS of 14.2743, representing an EPS surprise of +11.60%. The actual revenue for the quarter reached $7,752,000,000.00, compared to the estimated revenue of $7,594,740,702.00.

As of October 2, 2026, the current consensus target mean for BlackRock stands at $1,320.38, with a median target of $1,326.00. This mean target represents an implied change of +16.98% from previous levels. The prior consensus target mean was $1,320.92 as of September 15, 2026, reflecting a consensus target revision of -0.04%. In terms of aggregate recommendations for the period starting September 1, 2026, the consensus consists of 4 strong buy, 16 buy, 3 hold, 0 sell, and 0 strong sell recommendations, totaling 23 recommendations. This breakdown represents 87.0% positive, 13.0% hold, and 0.0% negative recommendations, which remains unchanged from the prior period starting August 1, 2026.

Other financial institutions have also recently maintained their views on BlackRock. On October 19, 2026, BMO Capital maintained its Outperform rating. On October 15, 2026, a cluster of analysts maintained their ratings: Wells Fargo maintained its Overweight rating, Keefe, Bruyette & Woods maintained its Outperform rating, JP Morgan maintained its Overweight rating, Morgan Stanley maintained its Overweight rating, and Barclays maintained its Overweight rating.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 20, 2026	TD Cowen	Hold	Buy	upgrade
October 19, 2026	BMO Capital	Outperform	Outperform	maintained
October 15, 2026	Wells Fargo	Overweight	Overweight	maintained
October 15, 2026	Keefe, Bruyette & Woods	Outperform	Outperform	maintained
October 15, 2026	JP Morgan	Overweight	Overweight	maintained
October 15, 2026	Morgan Stanley	Overweight	Overweight	maintained
October 15, 2026	Barclays	Overweight	Overweight	maintained

Cantor Fitzgerald Initiates Coverage of Modine Manufacturing at Overweight

2026-10-20T23:33:36Z

Fintel reports that on October 20, 2026, Cantor Fitzgerald initiated coverage of Modine Manufacturing (NYSE:MOD) (DB:MMF) with a Overweight recommendation.

Modine Manufacturing Company, headquartered in the United States, is an established provider in the thermal management sector. Founded in 1916, the company focuses on designing, manufacturing, and marketing heat exchange products across diverse industries, including automotive, industrial, and HVAC. Its operations are global, with a significant presence in North America, Europe, and Asia. Key projects and products include advanced cooling solutions for electric vehicle batteries, energy-efficient HVAC systems, and bespoke industrial thermal applications.

On October 20, 2026, the latest close for the stock was $146.80, following a pre-action close of $149.59 on October 19, 2026. The stock has seen a price change of -14.93% over one week, relative to a baseline close of $172.57 on October 13, 2026. Over a one-month period, the price change was -22.21% from a baseline close of $188.72 on September 18, 2026.

The company's latest earnings report on July 29, 2026, showed an actual EPS of 1.53, which was above the estimated EPS of 1.3043, representing a surprise of +17.30%. Actual revenue was $874,100,000.00, compared to the estimated revenue of $886,344,063.00. The upcoming earnings date is scheduled for November 3, 2026.

Apart from Cantor Fitzgerald's individual rating, the current consensus target mean as of October 2, 2026, was $328.93, with a median of $308.39, representing an implied change of +124.07%. The prior consensus target mean as of September 15, 2026, was $334.96, showing a revision of -1.80%. For the recommendation period of September 1, 2026, the aggregate recommendation total was 14, consisting of 4 strong buy, 9 buy, 1 hold, 0 sell, and 0 strong sell ratings. This represents 92.9% positive, 7.1% hold, and 0.0% negative recommendations, which is identical to the prior period of August 1, 2026.

Other recent analyst actions include Baird initiating coverage with an Outperform rating on October 6, 2026. Oppenheimer maintained an Outperform rating on October 2, 2026, and DA Davidson maintained a Buy rating on September 29, 2026.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 20, 2026	Cantor Fitzgerald		Overweight	initiated coverage
October 6, 2026	Baird		Outperform	initiated coverage
October 2, 2026	Oppenheimer	Outperform	Outperform	maintained
September 29, 2026	DA Davidson	Buy	Buy	maintained

Loop Capital downgrades Apple to Hold from Buy

2026-10-20T23:15:32Z

Fintel reports that on October 20, 2026, Loop Capital downgraded their outlook for Apple (NASDAQGS:AAPL) (BMV:AAPL) from Buy to Hold. This rating action occurred on the same day that MoffettNathanson maintained its Neutral rating for the company.

On October 20, 2026, the latest close for Apple was $339.73, following a pre-action close of $342.94 on October 19, 2026. The stock recorded a price change of -0.45% over one week, measured against a baseline close of $341.27 on October 13, 2026. Over a one-month period, the stock showed a price change of +1.07% from a baseline close of $336.13 on September 18, 2026.

As of October 2, 2026, the current consensus target mean for Apple was $331.39, and the median target was $336.60. This mean target represents an implied change of -2.45%. The prior consensus target mean was $329.05 as of September 15, 2026, reflecting a consensus target revision of +0.71%.

Broader analyst sentiment during the current recommendation period as of September 1, 2026, included 12 strong buy, 22 buy, 15 hold, 3 sell, and 1 strong sell recommendations, totaling 53. This represents 64.2% positive, 28.3% hold, and 7.5% negative recommendations. In the prior period as of August 1, 2026, the recommendations totaled 54, consisting of 13 strong buy, 24 buy, 14 hold, 3 sell, and 0 strong sell recommendations, representing 68.5% positive, 25.9% hold, and 5.6% negative recommendations.

Apple operates in the technology sector, focusing on consumer electronics, computer software, and online services. The company reported its latest earnings on July 30, 2026, with an actual EPS of 1.91 against an estimate of 1.9271, representing an EPS surprise of -0.89%. Actual revenue for the quarter was $109,417,000,000.00, compared to the estimated $110,814,663,937.00. The company's upcoming earnings date is scheduled for November 2, 2026, during the amc session.

Other recent analyst actions prior to this downgrade include JP Morgan maintaining an Overweight rating on October 12, 2026. On October 1, 2026, Needham reiterated its Hold rating, and Morgan Stanley maintained its Overweight rating. Additionally, Morgan Stanley reiterated its Overweight rating on September 29, 2026, and B of A Securities reiterated its Buy rating on September 23, 2026.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 20, 2026	Loop Capital	Buy	Hold	downgrade
October 20, 2026	MoffettNathanson	Neutral	Neutral	maintained
October 12, 2026	JP Morgan	Overweight	Overweight	maintained
October 1, 2026	Needham	Hold	Hold	reiterated
October 1, 2026	Morgan Stanley	Overweight	Overweight	maintained
September 29, 2026	Morgan Stanley	Overweight	Overweight	reiterated
September 23, 2026	B of A Securities	Buy	Buy	reiterated

Cantor Fitzgerald Initiates Coverage of Ensysce Biosciences at Overweight

2026-10-20T23:13:36Z

Fintel reports that on October 20, 2026, Cantor Fitzgerald initiated coverage of Ensysce Biosciences (NASDAQCM:ENSC) with a Overweight recommendation. This initiation of coverage occurred on October 20, 2026, with the stock closing at $0.51. The prior session on October 19, 2026, closed at $0.50. On the same day, Cantor Fitzgerald was the only firm recorded initiating coverage on the stock with an Overweight rating.

Ensysce Biosciences has experienced recent price fluctuations. The stock's latest close of $0.51 on October 20, 2026, represents a price change of -11.13% over the preceding week, relative to a baseline close of $0.57 on October 13, 2026. Over a longer one-month timeframe, the stock recorded a price change of +11.07% from a baseline close of $0.46 on September 18, 2026.

Separately from Cantor Fitzgerald's individual rating, the broader consensus target price for the company was recorded at a mean and median of $8.42 as of October 2, 2026. This target implies a potential change of +1,553.89% from the stock's valuation. The prior consensus target mean was also $8.42 on September 15, 2026, representing a consensus target revision of 0.00%. In terms of aggregate analyst sentiment, the current recommendation period starting July 1, 2024, shows a total of 7 recommendations, consisting of 2 strong buy, 4 buy, 1 hold, 0 sell, and 0 strong sell ratings. This breakdown results in a positive recommendation percentage of 85.7%, a hold percentage of 14.3%, and a negative percentage of 0.0%. These figures remain unchanged from the prior recommendation period starting June 1, 2024, which also reported 2 strong buy, 4 buy, 1 hold, 0 sell, and 0 strong sell ratings.

The company's financial performance was last reported on August 13, 2026, for its latest earnings period. During this release, Ensysce Biosciences reported an actual EPS of -0.2, compared to an estimated EPS of -0.51. The actual revenue for the period was $1,164,320.00, which exceeded the estimated revenue of $1,020,000.00. The company's upcoming earnings announcement is scheduled for November 12, 2026.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 20, 2026	Cantor Fitzgerald		Overweight	initiated coverage

Barclays Downgrades NuScale Power to Underweight from Equal-Weight

2026-10-20T22:04:14Z

Fintel reports that on October 20, 2026, Barclays downgraded their outlook for NuScale Power (NYSE:SMR) from Equal-Weight to Underweight. This action follows a prior decision by Barclays on July 23, 2026, when the firm maintained its rating on the stock at Equal-Weight.

Prior to this downgrade, on October 19, 2026, the stock's pre-action close was $5.69. This latest close of $5.69 on October 19, 2026, reflects a price change of -15.07% over one week, compared to a baseline close of $6.70 on October 12, 2026. Over a one-month period, the stock experienced a price change of -31.20% from a baseline close of $8.27 on September 18, 2026.

Separately, aggregate consensus target data as of October 2, 2026, shows a current consensus target mean of $12.19 and a median of $11.22. This current mean represents an implied change of +114.31% from the stock's trading levels. The prior consensus target mean was $12.78 as of September 15, 2026, representing a consensus target revision of -4.60%.

NuScale Power last reported earnings on August 5, 2026. For that period, the company reported an actual EPS of -0.13, compared to an estimate of -0.1299. Actual revenue was $75,000.00, which differed from the estimated revenue of $8,999,433.00. The company's upcoming earnings date is scheduled for November 5, 2026.

As of the current recommendation period starting September 1, 2026, the aggregate analyst recommendation distribution consists of 1 strong buy, 9 buy, 11 hold, 1 sell, and 1 strong sell recommendations, totaling 23. This distribution represents 43.5% positive, 47.8% hold, and 8.7% negative recommendations. These figures are unchanged from the prior recommendation period starting August 1, 2026, which also had 1 strong buy, 9 buy, 11 hold, 1 sell, and 1 strong sell recommendations, totaling 23, representing 43.5% positive, 47.8% hold, and 8.7% negative recommendations.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 20, 2026	Barclays	Equal-Weight	Underweight	downgrade

Leerink Partners Initiates Coverage of Kazia Therapeutics Limited - Depositary Receipt with Outperform Rating

2026-10-20T13:58:33Z

Fintel reports that on October 20, 2026, Leerink Partners initiated coverage of Kazia Therapeutics Limited - Depositary Receipt (NASDAQCM:KZIA) with an Outperform recommendation. This initiation of coverage represents a new rating from the analyst firm on this date. Prior to this action, the stock closed at $7.85 on October 19, 2026.

The market performance of Kazia Therapeutics Limited - Depositary Receipt shows a price change of -10.90% over one week, relative to a baseline close of $8.81 on October 12, 2026. Over a one-month period, the stock experienced a price change of -24.45% from a baseline close of $10.39 on September 18, 2026. The latest close for the security was recorded at $7.85 on October 19, 2026.

Separately from Leerink Partners' individual rating, aggregate consensus data shows a current consensus target mean of $27.03 and a median of $27.54 as of October 2, 2026. This mean target represents an implied change of +244.33%. The prior consensus target mean was $29.58 as of September 15, 2026, reflecting a consensus target revision of -8.62%. As of the current recommendation period on October 1, 2026, the aggregate recommendation breakdown consists of 3 strong buy, 8 buy, and 1 hold recommendations, totaling 12 recommendations. This represents 91.7% positive recommendations and 8.3% hold recommendations.

In its latest financial reports, Kazia Therapeutics Limited - Depositary Receipt reported earnings on March 19, 2026. The company reported an actual EPS of -0.805, compared to an estimated EPS of -0.3315. Actual revenue for the period was $253,000.00, exceeding the estimated revenue of $51,000.00.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 20, 2026	Leerink Partners		Outperform	initiated coverage

JP Morgan Upgrades Intel to Neutral from Underweight

2026-10-20T00:35:21Z

Fintel reports that on October 19, 2026, JP Morgan upgraded their outlook for Intel (NASDAQGS:INTC) (BATS-CHIXE:INLD) from Underweight to Neutral.

This rating action follows a prior action by JP Morgan on July 24, 2026, where the firm maintained its Underweight rating on the stock. Other recent analyst actions include Mizuho maintaining a Neutral rating on October 6, 2026, and TD Cowen reiterating a Hold rating on September 24, 2026.

On October 19, 2026, the latest close for Intel was $91.97. This compares to a pre-action close of $89.85 on October 16, 2026. Over a one-week period, the stock experienced a price change of -9.26% from a baseline close of $101.35 on October 12, 2026. Over a one-month period, the price change was -15.31% from a baseline close of $108.60 on September 18, 2026.

Intel Corporation, based in the United States, is a leader within the semiconductor industry. The company is primarily engaged in the design and manufacturing of computer components and related products, with an oeuvre spanning processors, chipsets, and memory technology. Key projects include the development of cutting-edge processor technologies such as the Core and Xeon series, advancements in AI-driven data analysis tools, and initiatives in autonomous vehicle technologies.

Intel's latest earnings were reported on July 23, 2026, with an actual EPS of 0.42 compared to an estimate of 0.2177, representing an EPS surprise of +92.93%. Actual revenue for the quarter was $16,128,000,000.00, exceeding the estimated revenue of $14,705,531,729.00. The company's upcoming earnings date is scheduled for October 29, 2026, during the amc session.

As of October 2, 2026, the current consensus target mean for Intel was $117.07, with a median target of $112.20, representing an implied change of +27.29%. This is a revision of +0.59% from the prior consensus target mean of $116.38 on September 15, 2026. In the recommendation period of September 1, 2026, the aggregate analyst recommendations consisted of 4 strong buy, 15 buy, 34 hold, 2 sell, and 0 strong sell ratings, totaling 55 recommendations. This represents 34.5% positive, 61.8% hold, and 3.6% negative recommendations. In the prior period of August 1, 2026, the recommendations consisted of 4 strong buy, 15 buy, 33 hold, 3 sell, and 0 strong sell ratings, totaling 55 recommendations, which represented 34.5% positive, 60.0% hold, and 5.5% negative recommendations.

Recent analyst actions

Recent analyst upgrades, downgrades, initiations, and maintained ratings
Date	Analyst	Prior	Latest recommendation	Action
October 19, 2026	JP Morgan	Underweight	Neutral	upgrade
October 6, 2026	Mizuho	Neutral	Neutral	maintained
September 24, 2026	TD Cowen	Hold	Hold	reiterated